Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same

Abstract

Stabilized ubiquitin-lytic peptide fusion polypeptides and a method of making the same by sub-cloning nucleic acid sequences coding for lytic peptides into a plasmid vector comprising a promoter and ubiquitin polypeptide coding sequence, wherein the ubiquitin polypeptide sequence is linked to the 5' end of the lytic peptide nucleic acid sequence and is translated as a fusion polypeptide.

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to ubiquitin-lytic peptide fusion gene constructs with enhanced stability and gene expression, ubiquitin-lytic peptide fusion protein products, and methods of making and using the same.

2. Description of Related Art

Naturally occurring lytic peptides play an important if not critical role as immunological agents in insects and have some, albeit secondary, defense functions in a range of other animals. The function of these peptides is to destroy procaryotic and other non-host cells by disrupting the cell membrane and promoting cell lysis. Common features of these naturally occurring lytic peptides include an overall basic charge, a small size (23-39 amino acid residues), and the ability to form amphipathic .alpha.-helices or .beta.-pleated sheets. Several types of lytic peptides have been identified: cecropins (described in U.S. Pat. Nos. 4,355,104 and 4,520,016 to Hultmark et al.), defensins, sarcotoxins, melittin, and magainins (described in U.S. Patent No. 4,810,777 to Zasloff). Each of these peptide types is distinguished by sequence and secondary structure characteristics.

Several hypotheses have been suggested for the mechanism of action of the lytic peptides: disruption of the membrane lipid bilayer by the anphipathic .alpha.-helix portion of the lytic peptide; lytic peptide formation of ion channels, which results in osmotically induced cytolysis; lytic peptide promotion of protein aggregation, which results in ion channel formation; and lytic peptide-induced release of phospholipids. Whatever the mechanism of lytic peptide-induced membrane damage, an ordered secondary conformation such as an amphipathic .alpha.-helix and positive charge density are features that appear to participate in the function of the lytic peptides.

Active synthetic analogs of naturally occurring lytic peptides have been produced and tested in vitro against a variety of procaryotic and eukaryotic cell types (see for example Arrowood, M. J., et al., J. Protozool. 38: 161s �199!; Jaynes, J. M., et al., FASEB J. 2: 2878 �1988!), including: gram positive and gram negative bacteria, fungi, yeast, protozoa, envelope viruses, virus-infected eukaryotic cells, and neoplastic or transformed mammalian cells. The results from these studies indicate that many of the synthetic lytic peptide analogs have similar or higher levels of lytic activity for many different types of cells, compared to the naturally occurring forms. In addition, the peptide concentration required to lyse microbial pathogens such as protozoans, yeast, and bacteria does not lyse normal mammalian cells. However, because previous work demonstrates that absolute sequence is not important as long as positive charge and amphipathy are preserved, the level of activity for a given synthetic peptide is difficult to predict.

The specificity of the lytic action also depends upon the concentration of the peptide and the type of membrane with which it interacts. Jaynes, J. M. et al., Peptide Research 2: 157 (1989) discuss the altered cytoskeletal characteristics of transformed or neoplastic mammalian cells that make them susceptible to lysis by the peptides. In these experiments, normal, human non-transformed cells remained unaffected at a given peptide concentration while transformed cells were lysed; however, when normal cells were treated with the cytoskeletal inhibitors cytochalasin D or colchicine, sensitivity to lysis increased. The experiments show that the action of lytic peptides on normal mammalian cells is limited. This resistance to lysis was most probably due to the well-developed cytoskeletal network of normal cells. In contrast, transformed cell lines which have well-known cytoskeletal deficiencies were sensitive to lysis. Because of differences in cellular sensitivity to lysis, lytic peptide concentration can be manipulated to effect lysis of one cell type but not another at the same locus.

Synthetic lytic peptide analogs can also act as agents of eukaryotic cell proliferation. Peptides that promote lysis of transformed cells will, at lower concentrations, promote cell proliferation in some cell types. This stimulatory activity is thought to depend on the channel-forming capability of the peptides, which somehow stimulates nutrient uptake, calcium influx or metabolite release, thereby stimulating cell proliferation (see Jaynes, J. M., Drug News & Perspectives 3: 69 �1990!; and Reed, W. A. et al., Molecular Reproduction and Development 31: 106 �1992!). Thus, at a given concentration, these peptides stimulate or create channels that can be beneficial to the normal mammalian cell in a benign environment where it is not important to exclude toxic compounds.

The synthetic lytic peptide analogs typically contain as few as 12 and as many as 40 amino acid residues. A phenylalanine residue is often positioned at the amino terminus of the protein to provide an aromatic moiety analogous to the tryptophan residue located near the amino terminus of natural cecropins and a UV-absorbing moiety with which to monitor the purification of the synthetic peptide. The basis for the design of these lytic peptide analogs is that a peptide of minimal length, having an amphipathic .alpha.-helical structural or a .beta.-pleated sheet motif, and overall positive charge density effects lytic activity.

Plant disease is one of the leading causes of crop loss in the world and is estimated to cause up to one third of total crop loss worldwide; for example, in the potato losses associated with bacterial disease are as high as 25% of worldwide production. Additionally, the cultivation of a few species of plants in a concentrated area exacerbates the spread of disease. Recent advances in genetic engineering have lead to the development of plants with disease resistant phenotypes based on the expression of recombinant DNA molecules. Transgenic tobacco plants were engineered with both a wound inducible PiII promoter and a constitutive 35S promoter to express two lytic peptides (SHIVA-1 and SB-37) with bacteriolytic activity. The SHIVA-1 plant demonstrated enhanced resistance to bacterial wilt caused by infection by Pseudomonas solanacearum (Jaynes, J. M., et al., Plant Science 89: 43 (1993); Destefano-Beltran, L., et al., Biotechnology in Plant Disease Control, pp. 175-189, Wiley-Liss (1993). Thus lytic peptides have valuable uses as anti-phytopathogenic agents. However, chemical synthesis of these lytic peptides is very expensive. Therefore, alternate, more economical and efficient methods of synthesis are needed, such as in vivo synthesis in host cells using recombinant DNA methods.

Recombinant DNA molecules are produced by sub-cloning genes into plasmids using a bacterial host intermediate. In principle this technique is straightforward. However, any sequence that interferes with bacterial growth through replication or production of products toxic to the bacteria, such a lytic peptides, are difficult to clone. Often, host bacterial cells containing mutated forms of the DNA sequences encoding toxic products will be selected. These mutations can result in either decreased expression or production of an inactive product. Bacteria will even insert mutations that prevent expression of a potentially toxic product in cloned genes controlled by a eukaryotic promoter that is not active in prokaryotes. The effect of this selection of mutated species leads to an Inability to isolate sub-clones containing a non-mutated gene of choice. Thus, some sub-cloned genes are unstable in their bacterial hosts, although this instability can only be shown empirically. The bacteriolytic activity of the lytic peptides is an obstacle to the production of stable recombinant DNA molecules that express the genes at high levels.

For example, in an attempt to sub-clone into a standard plasmid vector a gene coding for frog magainin, a natural lytic peptide, bacterial transformants contained deletion mutations in the magainin coding region. Another attempt was made to sub-clone a synthetic lytic peptide (SEQ ID NO. 98) into a standard plasmid vector (pUC19) containing the Cauliflower Mosaic virus 35S promoter. The resulting transformants were screened by polymerase chain reaction (PCR). However, out of 30 colonies, only 2 sub-clones gave faint positive signals. These two sub-clones were sequenced. The sequence showed that one clone had a point mutation that introduced a stop codon 3/4 of the way through the lytic peptide, and the other clone had a point mutation that changed the start codon from methionine to isoleucine. Both mutations would prevent the biosynthesis of the protein. Four more clones were analyzed, and of these four, one was sub-cloned an the wrong orientation, and three others had mutations introduced into the sequence. One of these sub-clones was selected for further analysis, but it inhibited the growth of its E. coli host. Thus, the production of recombinant DNA molecules coding for lytic peptides is difficult due to the uncertainty in obtaining the correct sub-clone.

Ubiquitin is a small, highly conserved protein present in all eukaryotes. Ubiquitins are encoded by gene families that are characterized by two types of basic structures. Polyubiquitin genes contain several direct repeats of ubiquitin, and ubiquitin-ribosomal fusion genes encode a single ubiquitin unit fused to the coding region for a small ribosomal associated protein. Both of these gene types are translated as polyproteins and then are processed By an endogenous ubiquitin hydrolase present in eukaryotes to release multiple ubiquitin proteins or ubiquitin and the ribosomal associated protein. A number of ubiquitin cDNAs or genomic clones have been isolated, including plant ubiquitin cDNAs and genomic clones from the potato (Garbarino, J. and Belknap, W., Plant Molecular Biology 24: 119 (1994); Garbarino. J. et al., Plant Molecular Biology 20: 235 (1992)).

U.S. Pat. Nos. 5,093,242 and 5,132,213 to Bachmair et al. teach the use of a ubiquitin cloning vector as a method of producing specified protein amino-termini. A recombinant DNA molecule was constructed with a protein coding gene fused at its amino terminus to a ubiquitin coding gene. Due to translation as a polypeptide and cleavage by hydrolases, a protein with any amino acid at the amino terminus can be generated. The amino terminus can be used to control the metabolic stability of the protein. However, the metabolic stability of the protein is dependent on the resulting amino acid at the amino-terminus, not the generation of a translation polypeptide.

The forgoing facts suggest that although lytic peptides as a class may include species that are efficacious in destroying bacteria, neoplastic cells, fungi, virus-infected cells, and protozoa, this lytic characteristic also decreases the stability of sub-cloned lytic peptides in host cells. This decreased stability hinders efforts to develop a more economical and efficient means of synthesizing lytic peptides.

It would therefore be a significant advance in the art, and is correspondingly an object of the present invention to develop a method of sub-cloning nucleotide sequences coding for lytic peptides into expression vectors, providing gene constructs with enhanced stability and gene expression and reduced toxicity.

SUMMARY OF THE INVENTION

The present invention relates generally to ubiquitin-lytic peptide fusion nucleic acid expression vectors comprising a promoter and ubiquitin polypeptide coding sequence ligated to a lytic peptide, ubiquitin-lytic peptide fusion protein products, and methods of making and using the same, as hereinafter more fully described.

It is another object of the invention to provide ubiquitin-lytic peptide fusion expression vectors and protein products derived therefrom.

It is another object of the invention to provide ubiquitin-lytic peptide fusion expression vectors that are expressed in plants having utility for promoting wound healing and combatting bacterial infections in plants.

It is a further object of this invention to provide ubiquitin-lytic peptide fusion polypeptides having utility for combatting protozoal infections, neoplasias, fungal infections, viral infections, and bacterial infections in mammals and plants.

It is yet another object of this invention to develop a method of sub-cloning polypeptide sequences in ubiquitin-fusion expression vectors with enhanced stability and gene expression.

It is yet another object of this invention to provide expression vectors containing constitutive and wound inducible ubiquitin promoters that are expressed in eukaryotic cells.

It is yet another object of this invention to provide expression vectors with procaryotic promoters that express ubiquitin-lytic peptide fusion genes in procaryotic hosts, the products of which can be cleaved in vitro by ubiquitin hydrolases.

These and other objects and advantages will be more fully apparent from the ensuing disclosure and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a map of a recombinant nucleic acid expression vector pUCUbi3-LP98 containing a 920 bp ubiquitin-ribosomal fusion gene promoter region linked to a 228 bp coding region for a ubiquitin polypeptide with a six bp BamHI site at the 3' end (SEQ ID NO. 93) that is fused at its 3' end to a gene coding for a lytic peptide (D5D*, SEQ ID NO. 98). The Ubi3 ubiquitin-lytic peptide nucleotide sequence corresponds to SEQ ID NO. 92. A nopaline synthase polyadenylation signal is located at the 3' end of the lytic peptide gene.

FIG. 2 is a map of a recombinant nucleic acid expression vector pUCUbi7-LP98 containing a 1220 bp polyubiquitin promoter region and 568 bp intron linked to a 228 bp coding region for a ubiquitin polypeptide with a six bp BamHI site at the 3' end (SEQ ID NO. 96) that is fused at its 3' end to a gene coding for a lytic peptide (D5D*, SEQ ID NO. 98). The Ubi7 ubiquitin-lytic peptide nucleotide sequence corresponds to SEQ ID NO. 95. A nopaline synthase polyadenylation signal is located at the 3' end of the lytic peptide gene.

DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS THEREOF

The disclosures of prior co-pending U.S. patent application No. 08/039,620 filed Jun. 4, 1993 in the names of Jesse M. Jaynes and Gordon R. Julian, U.S. patent application No. 08/148,889 filed Nov. 8, 1993 in the name of Gordon R. Julian, U.S. patent application No. 08/148,491 filed Nov. 8, 1993 in the name of Gordon R. Julian, U.S. patent application No. 08/225,476 filed Apr. 8, 1994 in the names of Jesse M. Jaynes and Gordon R.

Julian, and U.S. patent application No. 08/231,730 filed Apr. 20, 1994 in the names of Jesse M. Jaynes and Gordon R. Julian, are all hereby incorporated herein by reference in their entirety.

The term "amphipathic" as used herein refers to the distribution of hydrophobic and hydrophilic amino acid residues along opposing faces of an .alpha.-helix structure or other secondary conformation, which results in one face of the .alpha.-helix structure being predominantly hydrophobic and the other ace being predominantly hydrophilic. The degree of amphipathy of a peptide can be assessed by plotting the sequential amino acid residues on an Edmunson helical wheel (see also Kamtekar, S. et al., Science 262: 1680 (1993). The terms "peptide" and "polypeptide" as used herein refer to a molecule composed of a chain of amino acid residues and is intended to be construed as inclusive of polypeptides and peptides per se having molecular weights of up to 10,000 daltons, as well as proteins having molecular weights of greater that about 10,000 daltons, wherein the molecular weights are number average molecular weights. The term is also intended to be construed as inclusive of functional equivalents thereof when used in reference to a specific peptide coding sequence in the specification and claims herein. Functional equivalents of peptides and polypeptides include but are not limited to deletions, additions, and substitutions of amino acids in the polypeptide or peptide chain that do not adversely affect the overall function of the resulting peptide or polypeptide.

The term "plasmid" as used herein refers to a DNA molecule that is capable of autonomous replication within a host cell, either extrachromosomaily or as part of the host cell chromosome(s). The starting plasmids herein are commercially available, are publicly available on an unrestricted basis, or can be constructed from such available plasmids as disclosed herein and/or in accordance wish published procedures. In certain instances, as will be apparent to the ordinarily skilled artisan, other plasmids known in the art may be used interchangeable with plasmids described herein.

The term "ligation" as used herein refers to the process of forming phosphodiester bonds between two double-stranded DNA fragments. Unless otherwise specified, ligation is accomplished using standard procedures known to one skilled in the art.

The term "polymerase chain reaction," or "PCR" as used herein refers to a method for amplification of a desired nucleotide sequence in vitro, as described in U.S. Pat. No. 4,683,195, herein incorporated by reference in its entirety.

The term "nucleic acid" as used herein refers to deoxyribonucleic acid molecules (DNA) composed of a chain of deoxyribonucleotides and ribonucleic acid molecules (RNA) composed of a chain of ribonucleotides. The term "nucleic acid" as used herein is to be construed as including functional equivalents thereof when used in reference to a specific nucleotide sequence in the specification and claims herein. Functional equivalents of nucleic acid molecules include synonymous coding sequences with one or more codon substitutions and deletions or additions that do not effect the overall function of the resulting nucleic acid molecule. The degeneracy of the genetic code is well known to the art; therefore, synonymous coding sequences with one or more codon substitutions can be readily determined by one of ordinary skill in the art. Synonymous nucleotide coding sequences vary from the exemplified coding sequences but encode proteins of the same amino acid sequences as those specifically provided herein or proteins with similar function and are therefore also regarded as functional equivalents thereof.

The term "promoter" as used herein refers to an untranslated (i.e. one that does not result in a peptide or protein product) sequence upstream of the polypeptide coding region of a nucleotide sequence that controls transcription of a gene. Promoters typically fall into two classes, constitutive and inducible. Inducible promoters initiate high levels of transcription of the nucleic acid under their control in response to external stimuli. Constitutive promoters maintain a relatively constant level of transcription in a given cell. Suitable promoters for use in the present may include both procaryotic and eukaryotic promoters, with all ubiquitin promoters being preferred, solanaceous plant ubiquitin promoters being highly preferred, and potato ubiquitin promoters being most preferred. Additional control sequences such as ribosomal binding sites and enhancers may be included as control sequences when necessary.

The term "polyadenylation" sites as used herein refers to a control sequence located on the 3' end of a gene construct that provides a signal for cleavage and polyadenylation of the transcription unit expressed from the promoter. These control sequences are known to one skilled in the art

The term "expression" as used herein refers to transcription and or translation of a nucleic acid sequence coding for a protein or peptide.

In one embodiment, the present invention is directed to an isolated nucleotide sequence comprising a gene coding for a ubiquitin polypeptide and functional equivalents thereof, linked to a ubiquitin promoter and functional equivalents thereof. Suitable ubiquitin promoters for use in the present invention include, but are not limited to, ubiquitin promoters from solanaceous plants. Preferably, the ubiquitin promoter is a potato plant ubiquitin promoter and most preferably it is the potato Ubi3 or Ubi7 promoter. In embodiments wherein the isolated nucleotide sequence codes for the potato Ubi3 promoter linked to a gene coding for a ubiquitin polypeptide it has a nucleotide sequence according to SEQ ID NO. 93. The Ubi3 promoter alone also has utility as constitutive promoter in eukaryotes.

In embodiments wherein the isolated nucleotide sequence codes for the potato Ubi7 promoter linked to a gene coding for a ubiquitin polypeptide it has a nucleotide sequence according to SEQ ID NO. 96. The Ubi7 nucleotide sequence according to SEQ ID NO. 96 includes an intron that is part of the ubiquitin transcription unit. The intron is not required for gene expression from the Ubi7 promoter, thus the Ubi7 promoter region without the intron can be considered as a specific functional equivalent of the Ubi7 promoter. The Ubi7 promoter alone, with or without the intron, has utility as a wound inducible promoter in eukaryotes.

Preferably, the nucleotide sequence comprising the isolated ubiquitin promoter and gene coding for a ubiquitin polypeptide further comprises a gene coding for a lytic peptide ligated to the 3' end of the gene coding for a ubiquitin polypeptide. Suitable genes coding for a lytic peptide have a nucleotide sequence coding for any one of the amino acid sequences according to SEQ ID NO. 1-91 and 97-98.

In one preferred embodiment, the present invention is directed to an isolated nucleotide sequence comprising a gene coding for a lytic peptide ligated to the 3' end of the gene coding for a ubiquitin polypeptide linked to the Ubi3 ubiquitin promoter having a nucleotide sequence according to SEQ ID NO. 92. In an alternative of this embodiment, the present invention is directed to an isolated nucleotide sequence comprising a gene coding for a lytic peptide ligated to the 3' end of the gene coding for a ubiquitin polypeptide linked to a Ubi7 ubiquitin promoter having a nucleotide sequence according to SEQ ID NO. 95.

In another embodiment, the present invention is directed to a recombinant nucleic acid expression vector. The vector is characterized in that it comprises a nucleotide sequence wherein a gene coding for a ubiquitin polypeptide is linked to a ubiquitin promoter. Preferably, the present invention is directed to a recombinant nucleic acid expression vector characterized in that it further comprises a nucleotide sequence wherein a gene coding for a lytic peptide is ligated to the 3' end of the gene coding for a ubiquitin polypeptide linked to a ubiquitin promoter. Suitable vectors for use in this invention include any eukaryotic or procaryotic expression vectors known in the art. Preferable vectors for use in this invention are pUC19 and pCGN1547.

In another embodiment, the present invention is directed to a host cell that is transformed by a recombinant DNA expression vector comprising a gene coding for a ubiquitin polypeptide linked to a ubiquitin promoter. Suitable host cells for transformation in the present invention include all known bacterial host cells, with all strains of Escherichia coli and Agrobacterium tumefaciens being preferred. Preferably, the present invention is directed to a host cell the recombinant DNA expression vector further comprises a gene coding for a lytic peptide ligated to the 3' end of the gene coding for a ubiquitin polypeptide linked to a ubiquitin promoter. Suitable genes coding for a lytic peptide have a nucleotide sequence coding for any one of the amino acid sequences according :to SEQ ID NO. 1-91 and 97-98.

Preferably, the present invention is directed to a solanaceous plant host cell that is transformed by a recombinant DNA expression vector. Most preferably the solanaceous plant cell is a potato plant host cell.

In another embodiment, the present invention is directed to an isolated nucleotide sequence and functional equivalents thereof coding for a lytic peptide, where the nucleotide sequence has a sequence coding for any one of the amino acid sequences according to SEQ ID NO. 1-91 and 97-98.

In yet another embodiment, the present invention is directed to a purified ubiquitin polypeptide and functional equivalents thereof having an amino acid sequence according to SEQ ID NO. 94. This embodiment can further comprise a lytic peptide translationally fused to the carboxy terminus of a ubiquitin polypeptide.

In another embodiment, the present invention is directed to a method of sub-cloning nucleotide sequences coding for lytic peptides and expressing such sequences in cells. The method comprises a first step wherein a recombinant nucleic acid containing a gene coding for a lytic peptide ligated to a gene coding for a ubiquitin polypeptide linked to a ubiquitin promoter is produced in a first host cell. Suitable first host cells include any known bacterial host cells. Preferably, the first host cell is either an Escherichia coli cell or an Agrobacterium tumefaciens cell.

If the peptides are sub-cloned using such a ubiquitin-fusion expression vector, the following advantage results: the lytic peptide gene constructs have increased stability in the bacterial host. While not wishing to be bound by any one theory, the present inventors believe that the stability is due to the ubiquitin protein coding nucleic acid region fused to the 5' end of the lytic peptide nucleic acid sequence. Bacteria do not contain the endogenous hydrolase necessary for cleavage of the ubiquitin fusion protein, so the gene constructs are not toxic to bacteria, since active lytic peptide cannot released. Thus functional equivalents of the ubiquitin fusion polypeptide include any ubiquitin molecule that is capable of deceiving the host cell into viewing the gene construct and its products as non-toxic.

In a variation of this embodiment, the recombinant nucleic acid vector is isolated from the first host cell and expressed in a second host cell. Suitable second host cells are plant and animal cells, preferably a solanaceous plant cell, and most preferably a potato plant cell. In the second host cell the fusion gene is expressed at high levels and the polyprotein is cleaved by endogenous ubiquitin hydrolases to produce active lytic peptide. These transgenic hosts provide from the expression vector lytic peptides in vivo to combat bacterial infections, fungal infections, protozoal infections, virus infections, and neoplasias. In addition, expression vectors containing ubiquitin promoters that are either constitutive or wound inducible are used to express peptides in eukaryotes.

The present invention is also directed to a method of sub-cloning nucleotide sequences coding for lytic peptides and expressing such sequences in cells. The method comprises producing in a host cell a recombinant nucleic acid expression vector comprising a gene coding for a lytic peptide ligated to the 3' end of a gene coding for a ubiquitin promoter linked to a procaryotic promoter sequence. Suitable procaryotic promoters include those known to one skilled in the art to be active in prokaryotes and used in plasmid vectors for bacterial gene expression.

The recombinant nucleic acid expression vector is expressed in the host cell and ubiquitin-lytic peptide fusion polypeptides are isolated from the host. Preferably, the host cell is either an Escherichia coli cell or an Agrobacterium tumefaciens cell. The isolated ubiquitin-lytic peptide fusion polypeptides are then cleaved in vitro by ubiquitin hydrolases to release the lytic peptides from the ubiquitin polypeptide (see U.S. Pat. No. 5,196,321 to Bachmair et al.). The active lytic peptides are then used to treat bacterial infections, fungal infections, protozoal infections, virus infections, and neoplasias. These isolated lytic peptides are in some instances glyoxylated or methylated in vitro to stabilize against proteolytic digestion in vivo.

Ubiquitin fusion expression vectors thus have broad utility as cloning and expression vectors to stabilize and sub-clone lytic peptides nucleotide sequences, as well as a wide variety of protein coding nucleic acid sequences that are otherwise toxic to their hosts. The ubiquitin-lytic peptide expression vectors also have broad utility as an economical and efficient means to synthesize lytic peptides in host cells. These lytic peptides have utility for combatting protozoal infections, neoplasias, fungal infections, viral infections, and bacterial infections in mammals and plants.

The features and advantages of the invention are more fully shown by the following illustrative examples and embodiments, which are not to be limitingly construed as regard the broad scope, utility, and applicability of the invention.

EXAMPLE 1

Representative Lytic Peptides and Ubiquitin Polypeptide

Set out in Table 1 below as illustrative examples of lytic peptides are the amino acid sequences of families of related lytic peptides. These lytic peptides are designated for ease of reference as SEQ ID NO. 1-91 and 97-98. Nucleic acid sequences coding for these lytic peptides and functional equivalents thereof represent examples of lytic peptide nucleic acid sequences that are sub-cloned to make ubiquitin-lytic peptide fusion gene constructs and polypeptides. The ubiquitin polypeptide, designated for ease of reference as SEQ ID NO. 94, and functional equivalents thereof, represents an example of the 5' fusion ubiquitin polypeptide.

TABLE 1__________________________________________________________________________LYTIC PEPTIDE SEQUENCES__________________________________________________________________________SEQ ID NO. 1Phe Ala Val Ala Val Lys Ala Val Lys Lys Ala Val Lys Lys Val Lys 1 5 10 15Lys Ala Val Lys Lys Ala Val Lys Lys Lys Lys 20 25SEQ ID NO. 2Phe Ala Val Ala Val Lys Ala Val Ala Val Lys Ala Val Lys Lys Ala 1 5 10 15Val Lys Lys Val Lys Lys Ala Val Lys Lys Ala Val Lys Lys Lys Lys 20 25 30SEQ ID NO. 3Phe Ala Val Ala Val Lys Ala Val Ala Val Lys Ala Val Ala Val Lys 1 5 10 15Ala Val Lys Lys Ala Val Lys Lys Val Lys Lys Ala Val Lys Lys Ala 20 25 30Val Lys Lys Lys Lys 35SEQ ID NO. 4Phe Ala Val Ala Val Lys Ala Val Lys Lys Ala Val Lys Lys Val Lys 1 5 10 15Lys Ala Val Lys Lys Ala Val 20SEQ ID NO. 5Phe Ala Val Ala Val Lys Ala Val Ala Val Lys Ala Val Lys Lys Ala 1 5 10 15Val Lys Lys Val Lys Lys Ala Val Lys Lys Ala Val 20 25SEQ ID NO. 6Phe Ala Val Ala Val Lys Ala Val Ala Val Lys Ala Val Ala Val Lys 1 5 10 15Ala Val Lys Lys Ala Val Lys Lys Val Lys Lys Ala Val Lys Lys Ala 20 25 30ValSEQ ID NO. 7Phe Ala Val Gly Leu Arg Ala Ile Lys Arg Ala Leu Lys Lys Leu Arg 1 5 10 15Arg Gly Val Arg Lys Val Ala Lys Arg Lys Arg 20 25SEQ ID NO. 8Phe Ala Val Gly Leu Arg Ala Ile Lys Arg Ala Leu Lys Lys Leu Arg 1 5 10 15Arg Gly Val Arg Lys Val Ala 20SEQ ID NO. 9Lys Arg Lys Arg Ala Val Lys Arg Val Gly Arg Arg Leu Lys Lys Leu 1 5 10 15Ala Arg Lys Ile Ala Arg Leu Gly Val Ala Phe 20 25SEQ ID NO. 10Ala Val Lys Arg Val Gly Arg Arg Leu Lys Lys Leu Ala Arg Lys Ile 1 5 10 15Ala Arg Leu Gly Val Ala Phe 20SEQ ID NO. 11Phe Ala Val Gly Leu Arg Ala Ile Lys Arg Ala Leu Lys Lys Leu Arg 1 5 10 15Arg Gly Val Arg Lys Val Ala Lys Arg Lys Arg Lys Lys Asp Leu 20 25 30SEQ ID NO. 12Phe Ala Val Gly Leu Arg Ala Ile Lys Arg Ala Leu Lys Lys Leu Arg 1 5 10 15Arg Gly Val Arg Lys Val Ala Lys Asp Leu 20 25SEQ ID NO. 13Lys Arg Lys Arg Ala Val Lys Arg Val Gly Arg Arg Leu Lys Lys Leu 1 5 10 15Ala Arg Lys Ile Ala Arg Leu Gly Val Ala Phe Lys Asp Leu 20 25 30SEQ ID NO. 14Ala Val Lys Arg Val Gly Arg Arg Leu Lys Lys Leu Ala Arg Lys Ile 1 5 10 15Ala Arg Leu Gly Val Ala Phe Lys Asp Leu 20 25SEQ ID NO. 15Lys Lys Lys Lys Phe Val Lys Lys Val Ala Lys Lys Val Lys Lys Val 1 5 10 15Ala Lys Lys Val Ala Lys Val Ala Val Ala Val 20 25SEQ ID NO. 16Lys Lys Lys Lys Phe Val Lys Lys Val Ala Lys Lys Val Lys Lys Val 1 5 10 15Ala Lys Lys Val Ala Lys Val Ala Val Ala Lys Val Ala Val Ala Val 20 25 30SEQ ID NO. 17Lys Lys Lys Lys Phe Val Lys Lys Val Ala Lys Lys Val Lys Lys Val 1 5 10 15Ala Lys Lys Val Ala Lys Val Ala Val Ala Lys Val Ala Val Ala Lys 20 25 30Val Ala Val Ala Val 35SEQ ID NO. 18Phe Val Lys Lys Val Ala Lys Lys Val Lys Lys Val Ala Lys Lys Val 1 5 10 15Ala Lys Val Ala Val Ala Val 20SEQ ID NO. 19Phe Val Lys Lys Val Ala Lys Lys Val Lys Lys Val Ala Lys Lys Val 1 5 10 15Ala Lys Val Ala Val Ala Lys Val Ala Val Ala Val 20 25SEQ ID NO. 20Phe Val Lys Lys Val Ala Lys Lys Val Lys Lys Val Ala Lys Lys Val 1 5 10 15Ala Lys Val Ala Val Ala Lys Val Ala Val Ala Lys Val Ala Val Ala 20 25 30ValSEQ ID NO. 21Lys Lys Lys Lys Phe Val Lys Lys Val Ala Lys Val Ala Lys Lys Val 1 5 10 15Ala Lys Val Ala Lys Lys Val Ala Lys Lys Val 20 25SEQ ID NO. 22Lys Lys Lys Lys Phe Val Lys Lys Val Ala Lys Val Ala Lys Lys Val 1 5 10 15Ala Lys Val Ala Lys Lys Val Ala Lys Lys Val Ala Lys Lys Val Ala 20 25 30SEQ ID NO. 23Lys Lys Lys Lys Phe Val Lys Lys Val Ala Lys Val Ala Lys Lys Val 1 5 10 15Ala Lys Val Ala Lys Lys Val Ala Lys Lys Val Ala Lys Lys Val Ala 20 25 30Lys Val Ala Lys Lys 35SEQ ID NO. 24Phe Val Lys Lys Val Ala Lys Val Ala Lys Lys Val Ala Lys Val Ala 1 5 10 15Lys Lys Val Ala Lys Lys Val 20SEQ ID NO. 25Phe Val Lys Lys Val Ala Lys Val Ala Lys Lys Val Ala Lys Val Ala 1 5 10 15Lys Lys Val Ala Lys Lys Val Ala Lys Lys Val Ala 20 25SEQ ID NO. 26Phe Val Lys Lys Val Ala Lys Val Ala Lys Lys Val Ala Lys Val Ala 1 5 10 15Lys Lys Val Ala Lys Lys Val Ala Lys Lys Val Ala Lys Val Ala Lys 20 25 30LysSEQ ID NO. 27Phe Val Lys Lys Val Ala Lys Val Ala Lys Lys Val Ala Lys Val Ala 1 5 10 15Lys Lys Val Ala Lys Lys Val Lys Lys Lys Lys 20 25SEQ ID NO. 28Phe Val Lys Lys Val Ala Lys Val Ala Lys Lys Val Ala Lys Val Ala 1 5 10 15Lys Lys Val Ala Lys Lys Val Ala Lys Lys Val Ala Lys Lys Lys Lys 20 25 30SEQ ID NO. 29Phe Val Lys Lys Val Ala Lys Val Ala Lys Lys Val Ala Lys Val Ala 1 5 10 15Lys Lys Val Ala Lys Lys Val Ala Lys Lys Val Ala Lys Val Ala Lys 20 25 30Lys Lys Lys Lys Lys 35SEQ ID NO. 30Phe Lys Val Lys Ala Lys Val Lys Ala Lys Val Lys Lys Lys Lys Lys 1 5 10 15SEQ ID NO. 31Phe Lys Val Lys Ala Lys Val Lys Ala Lys Val Lys Ala Lys Val Lys 1 5 10 15Ala Lys Lys Lys Lys 20SEQ ID NO. 32Phe Lys Val Lys Ala Lys Val Lys Ala Lys Val Lys Ala Lys Val Lys 1 5 10 15Ala Lys Val Lys Ala Lys Val Lys Lys Lys Lys 20 25SEQ ID NO. 33Phe Lys Val Lys Ala Lys Val Lys Ala Lys Val Lys 1 5 10SEQ ID NO. 34Phe Lys Val Lys Ala Lys Val Lys Ala Lys Val Lys Ala Lys Val Lys 1 5 10 15AlaSEQ ID NO. 35Phe Lys Val Lys Ala Lys Val Lys Ala Lys Val Lys Ala Lys Val Lys 1 5 10 15Ala Lys Val Lys Ala Lys Val 20SEQ ID NO. 36Lys Lys Lys Lys Phe Lys Val Lys Ala Lys Val Lys Ala Lys Val Lys 1 5 10 15SEQ ID NO. 37Lys Lys Lys Lys Phe Lys Val Lys Ala Lys Val Lys Ala Lys Val Lys 1 5 10 15Ala Lys Val Lys Ala 20SEQ ID NO. 38Lys Lys Lys Lys Phe Lys Val Lys Ala Lys Val Lys Ala Lys Val Lys 1 5 10 15Ala Lys Val Lys Ala Lys Val Lys Ala Lys Val 20 25SEQ ID NO. 39Phe Lys Lys Val Lys Lys Val Ala Lys Lys Val Cys Lys Cys Val Lys 1 5 10 15Lys Ala Val Lys Lys Val`Lys Lys Phe 20 25SEQ ID NO. 40Phe Ala Val Ala Val Lys Ala Val Lys Lys Ala Val Lys Lys Val Lys 1 5 10 15Lys Ala Val Lys Lys Ala Val Cys Cys Cys Cys 20 25SEQ ID NO. 41Cys Cys Cys Cys Phe Val Lys Lys Val Ala Lys Lys Val Lys Lys Val 1 5 10 15Ala Lys Lys Val Ala Lys Val Ala Val Ala Val 20 25SEQ ID NO. 42Phe Ala Val Ala Val Lys Ala Val Lys Lys Ala Val Lys Lys Val Lys 1 5 10 15Lys Ala Val Lys Lys Ala Val Ser Ser Ser Ser 20 25SEQ ID NO. 43Ser Ser Ser Ser Phe Val Lys Lys Val Ala Lys Lys Val Lys Lys Val 1 5 10 15Ala Lys Lys Val Ala Lys Val Ala Val Ala Val 20 25SEQ ID NO. 44Phe Ala Leu Ala Leu Lys Ala Leu Lys Lys Ala Leu Lys Lys Leu Lys 1 5 10 15Lys Ala Leu Lys Lys Ala Leu 20SEQ ID NO. 45Leu Ala Lys Lys Leu Ala Lys Lys Leu Lys Lys Leu Ala Lys Lys Leu 1 5 10 15Ala Lys Leu Ala Leu Ala Phe 20SEQ ID NO. 46Phe Ala Phe Ala Phe Lys Ala Phe Lys Lys Ala Phe Lys Lys Phe Lys 1 5 10 15Lys Ala Phe Lys Lys Ala Phe 20SEQ ID NO. 47Phe Ala Ile Ala Ile Lys Ala Ile Lys Lys Ala Ile Lys Lys Ile Lys 1 5 10 15Lys Ala Ile Lys Lys Ala Ile 20SEQ ID NO. 48Phe Ala Lys Lys Phe Ala Lys Lys Phe Lys Lys Phe Ala Lys Lys Phe 1 5 10 15Ala Lys Phe Ala Phe Ala Phe 20SEQ ID NO. 49Phe Lys Arg Leu Ala Lys Ile Lys Val Leu Arg Leu Ala Lys Ile Lys 1 5 10 15ArgSEQ ID NO. 50Lys Leu Lys Leu Ala Val Lys Leu Val Gly Leu Leu Arg Lys Lys Arg 1 5 10 15Ala Leu Lys Ile Ala Leu Arg Gly Val Ala Lys Arg Ala Gly Arg Leu 20 25 30Ala Val Arg Lys Phe 35SEQ ID NO. 51Phe Ala Arg Ala Arg Lys Ala Arg Lys Lys Ala Arg Lys Lys Arg Lys 1 5 10 15Lys Ala Arg Lys Lys Ala Arg Lys Asp Arg 20 25SEQ ID NO. 52Phe Ala Val Ala Val Cys Ala Val Cys Cys Ala Val Cys Cys Val Cys 1 5 10 15Cys Ala Val Cys Cys Ala Val 20SEQ ID NO. 53Phe Ala Val Ala Val Ser Ala Val Ser Ser Ala Val Ser Ser Val Ser 1 5 10 15Ser Ala Val Ser Ser Ala Val 20SEQ ID NO. 54Phe Ala Val Ala Val Ser Ala Val Ser Ser Ala Val Ser Ser Val Ser 1 5 10 15Ser Ala Val Ser Ser Ala Val Ser Ser Ser Ser 20 25SEQ ID NO. 55Phe Ala Lys Lys Phe Ala Lys Lys Phe Lys Lys Phe Ala Lys Lys Phe 1 5 10 15Ala Lys Phe Ala Phe Ala Phe Lys Lys Lys Lys 20 25SEQ ID NO. 56Lys Lys Lys Lys Phe Ala Lys Lys Phe Ala Lys Lys Phe Lys Lys Phe 1 5 10 15Ala Lys Lys Phe Ala Lys Phe Ala Phe Ala Phe 20 25SEQ ID NO. 57Phe Ala Arg Lys Phe Leu Lys Arg Phe Lys Lys Phe Val Arg Lys Phe 1 5 10 15Ile Arg Phe Ala Phe Leu Phe 20SEQ ID NO. 58Phe Ala Arg Lys Phe Leu Lys Arg Phe Lys Lys Phe Val Arg Lys Phe 1 5 10 15Ile Arg Phe Ala Phe Leu Phe Lys Arg Lys Arg 20 25SEQ ID NO. 59Lys Arg Lys Arg Phe Ala Arg Lys Phe Leu Lys Arg Phe Lys Lys Phe 1 5 10 15Val Arg Lys Phe Ile Arg Phe Ala Phe Leu Phe 20 25SEQ ID NO. 60Ile Ala Lys Lys Ile Ala Lys Lys Ile Lys Lys Ile Ala Lys Lys Ile 1 5 10 15Ala Lys Ile Ala Ile Ala Ile 20SEQ ID NO. 61Ile Ala Lys Lys Ile Ala Lys Lys Ile Lys Lys Ile Ala Lys Lys Ile 1 5 10 15Ala Lys Ile Ala Ile Ala Ile Lys Lys Lys Lys 20 25SEQ ID NO. 62Lys Lys Lys Lys Ile Ala Lys Lys Ile Ala Lys Lys Ile Lys Lys Ile 1 5 10 15Ala Lys Lys Ile Ala Lys Ile Ala Ile Ala Ile 20 25SEQ ID NO. 63Ile Ala Arg Lys Ile Leu Lys Arg Ile Lys Lys Ile Val Arg Lys Phe 1 5 10 15Ile Arg Ile Ala Ile Leu Ile 20SEQ ID NO. 64Ile Ala Arg Lys Ile Leu Lys Arg Ile Lys Lys Ile Val Arg Lys Phe 1 5 10 15Ile Arg Ile Ala Ile Leu Ile Lys Arg Lys Arg 20 25SEQ ID NO. 65Lys Arg Lys Arg Ile Ala Arg Lys Ile Leu Lys Arg Ile Lys Lys Ile 1 5 10 15Val Arg Lys Phe Ile Arg Ile Ala Ile Leu Ile 20 25SEQ ID NO. 66Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Leu Arg Ala Lys Ile Lys 1 5 10 15LeuSEQ ID NO. 67Lys Arg Lys Arg Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Leu Arg 1 5 10 15Ala Lys Ile Lys Leu 20SEQ ID NO. 68Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Leu Arg Ala Lys Ile Lys 1 5 10 15Leu Lys Arg Lys Arg 20SEQ ID NO. 69Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Leu Arg Ala Lys Ile Lys 1 5 10 15Leu Arg Val Lys Leu Lys Ile 20SEQ ID NO. 70Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Leu Arg Ala Lys Ile Lys 1 5 10 15Leu Arg Val Lys Leu Lys Ile Lys Arg Lys Arg 20 25SEQ ID NO. 71Lys Arg Lys Arg Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Leu Arg 1 5 10 15Ala Lys Ile Lys Leu Arg Val Lys Leu Lys Ile 20 25SEQ ID NO. 72Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Leu Arg Ala Lys Ile Lys 1 5 10 15Leu Arg Val Lys Leu Lys Ile Arg Ala Arg Ile Lys Leu 20 25SEQ ID NO. 73Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Leu Arg Ala Lys Ile Lys 1 5 10 15Leu Arg Val Lys Leu Lys Ile Arg Ala Arg Ile Lys Leu Lys Arg Lys 20 25 30ArgSEQ ID NO. 74Lys Arg Lys Arg Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Leu Arg 1 5 10 15Ala Lys Ile Lys Leu Arg Val Lys Leu Lys Ile Arg Ala Arg Ile Lys 20 25 30LeuSEQ ID NO. 75Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Leu Arg Ala Lys Ile Lys 1 5 10 15Leu Val Phe Ala Ile Leu Leu 20SEQ ID NO. 76Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Leu Arg Ala Lys Ile Lys 1 5 10 15Leu Val Phe Ala Ile Leu Leu Lys Arg Lys Arg 20 25SEQ ID NO. 77Lys Arg Lys Arg Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Leu Arg 1 5 10 15Ala Lys Ile Lys Leu Val Phe Ala Ile Leu Leu 20 25SEQ ID NO. 78Val Phe Ala Ile Leu Leu Phe Lys Leu Arg Ala Lys Ile Lys Val Arg 1 5 10 15Leu Arg Ala Lys Ile Lys Leu 20SEQ ID NO. 79Val Phe Ala Ile Leu Leu Phe Lys Leu Arg Ala Lys Ile Lys Val Arg 1 5 10 15Leu Arg Ala Lys Ile Lys Leu Arg Lys Arg 20 25SEQ ID NO. 80Lys Arg Lys Arg Val Phe Ala Ile Leu Leu Phe Lys Leu Arg Ala Lys 1 5 10 15Ile Lys Val Arg Leu Arg Ala Lys Ile Lys Leu 20 25SEQ ID NO. 81Val Gly Glu Cys Val Arg Gly Arg Cys Pro Ser Gly Met Cys Cys Ser 1 5 10 15Gln Phe Gly Tyr Cys Gly Lys Gly Pro Lys Tyr Cys Gly 20 25SEQ ID NO. 82Val Gly Glu Cys Val Arg Gly Arg Cys Pro Ser Gly Met Cys Cys Ser 1 5 10 15Gln Phe Gly Tyr Cys Gly Lys Gly Pro Lys Tyr Cys Gly Arg 20 25 30SEQ ID NO. 83Leu Gly Asp Cys Leu Lys Gly Lys Cys Pro Ser Gly Met Cys Cys Ser 1 5 10 15Asn Tyr Gly Phe Cys Gly Arg Gly Pro Arg Phe Cys Gly Lys 20 25 30SEQ ID NO. 84Gln Cys Ile Gly Asn Gly Gly Arg Cys Asn Glu Asn Val Gly Pro Pro 1 5 10 15Tyr Cys Cys Ser Gly Phe Cys Leu Arg Gln Pro Gly Gln Gly Tyr Gly 20 25 30Tyr Cys Lys Asn Arg 35SEQ ID NO. 85Cys Ile Gly Asn Gly Gly Arg Cys Asn Glu Asn Val Gly Pro Pro Tyr 1 5 10 15Cys Cys Ser Gly Phe Cys Leu Arg Gln Pro Asn Gln Gly Tyr Gly Val 20 25 30Cys Arg Asn Arg 35SEQ ID NO. 86Cys Ile Gly Gln Gly Gly Lys Cys Gln Asp Gln Leu Gly Pro Pro Phe 1 5 10 15Cys Cys Ser Gly Tyr Cys Val Lys Asn Pro Gln Asn Gly Phe Gly Leu 20 25 30Cys Lys Gln Lys 35SEQ ID NO. 87Gln Lys Leu Cys Glu Arg Pro Ser Gly Thr Trp Ser Gly Val Cys Gly 1 5 10 15Asn Asn Asn Ala Cys Lys Asn Gln Cys Ile Asn Leu Glu Lys Ala Arg 20 25 30His Gly Ser Cys Asn Tyr Val Phe Pro Ala His Lys 35 40SEQ ID NO. 88Gln Arg Val Cys Asp Lys Pro Ser Gly Thr Trp Ser Gly Leu Cys Gly 1 5 10 15Asn Asn Asn Ala Cys Arg Gln Asn Cys Ile Gln Val Asp Arg Ala Lys 20 25 30Lys Gly Ser Cys Gln Phe Leu Tyr Pro Ala Lys Lys 35 40SEQ ID NO. 89Gln Lys Leu Cys Gln Arg Pro Ser Gly Thr Trp Ser Gly Val Cys Gly 1 5 10 15Asn Asn Asn Ala Cys Lys Asn Gln Cys Ile Arg Leu Glu Lys Ala Arg 20 25 30His Gly Ser Cys 35SEQ ID NO. 90Gln Arg Val Cys Asn Lys Pro Ser Gly Thr Trp Ser Gly Leu Cys Gly 1 5 10 15Asn Asn Asn Ala Cys Arg Gln Asn Cys Ile Lys Val Asp Arg Ala Lys 20 25 30Lys Gly Ser Cys 35SEQ ID NO. 91Met Leu Glu Glu Leu Phe Glu Glu Met Thr Glu Phe Ile Glu Glu Val 1 5 10 15Ile Glu Thr Met 20SEQ ID NO. 94Met Gln Ile Phe Val Lys Thr Leu 1 5Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Ser Ser Asp Thr 10 15 20Ile Asp Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile 25 30 35Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu 40 45 50Glu Asp Gly Arg Thr Leu Ala Asp Tyr Asn Ile Gln Lys Glu 55 60Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly Gly Ser65 70 75SEQ ID NO. 97Lys Arg Lys Arg Ala Val Lys Arg Val Gly Arg Arg Leu Lys Lys Leu 1 5 10 15Ala Arg Lys Ile Ala Arg Leu Gly Val Ala Lys Leu Ala Gly Leu Arg 20 25 30Ala Val Leu Lys Phe 35SEQ ID NO. 98Ala Val Lys Arg Val Gly Arg Arg Leu Lys Lys Leu Asp Arg Lys Ile 1 5 10 15Asp Arg Leu Gly Val Asp Phe 20__________________________________________________________________________

EXAMPLE 2

Construction of Ubiquitin-Lytic Peptide Fusion Plasmids With Ubiquitin-ribosomal Fusion Gene Promoter (Ubi3)

Exemplary and preferred pUC19 and pCGN1547 plasmid vectors containing a potato (Solanum tuberosum) ubiquitin-ribosomal fusion promoter (Ubi3), a region coding for a ubiquitin polypeptide, and a gene coding for a lytic peptide are constructed.

To obtain the genomic clone containing a ubiquitin-ribosomal fusion promoter and ubiquitin polypeptide coding region, a .alpha.FIXII potato genomic library is first prescreened using PCR. The PCR primers are homologous to regions of the ubiquitin-ribosomal fusion cDNA (see Garbarino J., et al., Plant Molecular Biology 20: 235(1992); Garbarino J. and Belknap W., Plant Molecular Biology 30 24: 119 (1994); both of which are hereby incorporated by reference herein in their entirety). A primer 5' to the beginning ATG of ubiquitin and a primer complementary to a sequence near the 5' end of the ribosomal protein are used.

The library is plated in 22 aliquots containing approximately 0.5.times.10.sup.6 pfu (plaque forming units) each on an E. coli lawn. A plug is taken from each of the 22 resulting plaques and the eluant from each is subjected to PCR under standard conditions. The PCR products are run on agarose gels. The gels are then blotted and probed with the ubiquitin coding region of the ubiquitin-ribosomal fusion cDNA according to standard conditions. Two of the plugs produce PCR products that hybridize to the cDNA probe., Both of these are the correct size for the predicted ubiquitin-ribosomal fusion genomic fragment.

The eluants from these two plugs are then plated and screened with the ubiquitin coding region of the ubiquitin-ribosomal fusion cDNA according to standard conditions. For verification, the positive plaques from the initial screen are replated and screened with a probe containing both the ribosomal protein-coding region and the 3' end of the potato ubiquitin-ribosomal fusion cDNA.

The genomic clones are sequenced using Sequenase version 2.0 15 (United States Biochemical Corporation) or Promega fmol DNA Sequencing System using standard conditions. A genomic clone containing both the ubiquitin-ribosomal fusion promoter region and the ubiquitin-ribosomal fusion coding region is identified.

A chimeric gene is then constructed with a portion of the potato ubiquitin-ribosomal fusion genomic clone ligated to a lytic peptide gene. PCR is used to generate the Ubi3 promoter and ubiquitin portion of the chimeric gene. The Ubi3 promoter region includes the 920 bp promoter region upstream of the ubiquitin ATG, and the ubiquitin polypeptide coding region is 228 bp plus 6 bp of a BamHI restriction site at the 3' end (SEQ ID NO. 93). The primers contain BamHI restriction sites and are homologous to the 5' end of the Ubi3 promoter and to the 3' end of the ubiquitin polypeptide coding region. The ubiquitin-ribosomal fusion genomic clone is used as the amplification template. This insert is first sub-cloned into she plasmid pCGN1547, as described in Garbarino et al., Plant Molecular Biology 24: 119 (1994). The Ubi3 insert is then isolated from pCGN1547 using the BamHI sites and ligated into pUCl9 under standard conditions. Transformation of E. coli is done according to standard conditions and correct sub-clones are confirmed by mini-prep or PCR DNA analysis. This plasmid is designated pUCUbi3.

A nucleotide fragment coding for the lytic peptide (corresponding to the amino acid sequence SEQ ID NO. 98) is synthesized using a nucleic acid synthesizer, adding a stop codon to the 3' end, and used as a PCR template. The 5' PCR primer homologous to the lytic peptide nucleotide sequence contains a BamHI site, and the 3' primer contains an XbaI site. These sites are used to sub-clone the PCR generated insert into pUC19. A nopaline synthase polyadenylation signal (NOS3' ) is then cloned 3' to the lytic peptide sequence. Following sequence analysis, the BamHI insert containing the Ubi3 promoter and ubiquitin coding region (SEQ ID NO. 93) is cloned 5' to the lytic peptide.

After transforming E. coli under standard conditions, pUC19 sub-clones are selected for mini-prep or PCR DNA analysis according to standard conditions. The direction of the promoter is confirmed and the junction sequences are verified by sequencing according to standard conditions. The resulting Ubi3 ubiquitin-lytic peptide fusion gene construct corresponds to SEQ ID NO. 92. Unlike previous cloning attempts using the CaMV35S promoter, as described in the Background section, the sequence does not reveal any point mutations in the lytic peptide sub-clones. The plasmid is stable in the E. coli host and did not inhibit its growth.

The resulting pUC19 recombinant plasmid is shown in the plasmid map in FIG. 1. The sequence for the Ubi3-ubiquitin insert containing the ubiquitin-ribosomal fusion gene promoter and the ubiquitin coding region corresponds to SEQ ID NO. 93 in Table 2 below. The sequence for the chimeric Ubi3 ubiquitin-lytic peptide fusion gene construct corresponds to SEQ ID NO. 92 in Table 2 below. This plasmid is designated as pUCUbi3-LP98.

The entire Ubi3 ubiquitin-lytic peptide fusion gene construct, including the polyadenylation site, was isolated from pUC19 as an Asp718/HindIII restriction fragment and sub-cloned into the pCGN1547 Agrobacterium vector for use in plant transformation (see McBride, et al., Plant Molecular Biology 14:269 (1990). This plasmid is designated as pCGNUbi3-LP98.

TABLE 2__________________________________________________________________________NUCLEOTIDE SEQUENCE OF POTATO UBIQUITIN-RIBOSOMALFUSION PROMOTER (UBI3) AND UBIQUITIN CODING REGIONINSERT, AND UBIQUITIN-LYTIC PEPTIDE FUSION GENE CONSTRUCT__________________________________________________________________________SEQ ID NO. 92CCAAAGCACA TACTTATCGA TTTAAATTTC ATCGAAGAGA TTAATATCGA 50ATAATCATAT ACATACTTTA AATACATAAC AAATTTTAAA TACATATATC 100TGGTATATAA TTAATTTTTT AAAGTCATGA AGTATGTATC AAATACACAT 150ATGGAAAAAA TTAACTATTC ATAATTTAAA AAATAGAAAA GATACATCTA 200GTGAAATTAG GTGCATGTAT CAAATACATT AGGAAAAGGG CATATATCTT 250GATCTAGATA ATTAACGATT TTGATTTATG TATAATTTCC AAATGAAGGT 300TTATATCTAC TTCAGAAATA ACAATATACT TTTATCAGAA CATTCAACAA 350AGCAACAACC AACTAGAGTG AAAAATACAC ATTGTTCTCT AGACATACAA 400AATTGAGAAA AGAATCTCAA AATTTAGAGA AACAAATCTG AATTTCTAGA 450AGAAAAAAAT AATTATGCAC TTTGCTATTG CTCGAAAAAT AAATGAAAGA 500AATTAGACTT TTTTAAAAGA TGTTAGACTA GATATACTCA AAAGCTATTA 550AAGGAGTAAT ATTCTTCTTA CATTAAGTAT TTTAGTTACA GTCCTGTAAT 600TAAAGACACA TTTTAGATTG TATCTAAACT TAAATGTATC TAGAATACAT 650ATATTTGAAT GCATCATATA CATGTATCCG ACACACCAAT TCTCATAAAA 700AACGTAATAT CCTAAACTAA TTTATCCTTC AAGTCAACTT AAGCCCAATA 750TACATTTTCA TCTCTAAAGG CCCAAGTGGC ACAAAATGTC AGGCCCAATT 800ACGAAGAAAA GGGCTTGTAA AACCCTAATA AAGTGGCACT GGCAGAGCTT 850ACACTCTCAT TCCATCAACA AAGAAACCCT AAAAGCCGCA GCGCCACTGA 900TTTCTCTCCT CCAGGCGAAG ATG CAG ATC TTC GTG AAG ACC TTA 944 Met Gln Ile Phe Val Lys Thr Leu 1 5ACG GGG AAG ACG ATC ACC CTA GAG GTT GAG TCT TCC GAC ACC 986Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Ser Ser Asp Thr 10 15 20ATC GAC AAT GTC AAA GCC AAG ATC CAG GAC AAG GAA GGG ATT 1028Ile Asp Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile 25 30 35CCC CCA GAC CAG CAG CGT TTG ATT TTC GCC GGA AAG CAG CTT 1070Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu 40 45 50GAG GAT GGT CGT ACT CTT GCC GAC TAC AAC ATC.degree.CAG AAG GAG 1112Glu Asp Gly Arg Thr Leu Ala Asp Tyr Asn Ile Gln Lys Glu 55 60TCA ACT CTC CAT CTC GTG CTC CGT CTC CGT GGT GGT 1148Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly65 70 75GGA TCC GCT GTT AAA AGA GTG GGT CGT AGG TTG AAA AAG TTG 1190Gly Ser Ala Val Lys Arg Val Gly Arg Arg Leu Lys Lys Leu 80 85 90GAC CGT AAG ATT GAT AGG TTA GGA GTT GAT TTT TGATC 1228Asp Arg Lys Ile Asp Arg Leu Gly Val Asp Phe 95 100SEQ ID NO. 93CCAAAGCACA TACTTATCGA TTTAAATTTC ATCGAAGAGA TTAATATCGA 50ATAATCATAT ACATACTTTA AATACATAAC AAATTTTAAA TACATATATC 100TGGTATATAA TTAATTTTTT AAAGTCATGA AGTATGTATC AAATACACAT 150ATGGAAAAAA TTAACTATTC ATAATTTAAA AAATAGAAAA GATACATCTA 200GTGAAATTAG GTGCATGTAT CAAATACATT AGGAAAAGGG CATATATCTT 250GATCTAGATA ATTAACGATT TTGATTTATG TATAATTTCC AAATGAAGGT 300TTATATCTAC TTCAGAAATA ACAATATACT TTTATCAGAA CATTCAACAA 350AGCAACAACC AACTAGAGTG AAAAATACAC ATTGTTCTCT AGACATACAA 400AATTGAGAAA AGAATCTCAA AATTTAGAGA AACAAATCTG AATTTCTAGA 450AGAAAAAAAT AATTATGCAC TTTGCTATTG CTCGAAAAAT AAATGAAAGA 500AATTAGACTT TTTTAAAAGA TGTTAGACTA GATATACTCA AAAGCTATTA 550AAGGAGTAAT ATTCTTCTTA CATTAAGTAT TTTAGTTACA GTCCTGTAAT 600TAAAGACACA TTTTAGATTG TATCTAAACT TAAATGTATC TAGAATACAT 650ATATTTGAAT GCATCATATA CATGTATCCG ACACACCAAT TCTCATAAAA 700AACGTAATAT CCTAAACTAA TTTATCCTTC AAGTCAACTT AAGCCCAATA 750TACATTTTCA TCTCTAAAGG CCCAAGTGGC ACAAAATGTC AGGCCCAATT 800ACGAAGAAAA GGGCTTGTAA AACCCTAATA AAGTGGCACT GGCAGAGCTT 850ACACTCTCAT TCCATCAACA AAGAAACCCT AAAAGCCGCA GCGCCACTGA 900TTTCTCTCCT CCAGGCGAAG ATG CAG ATC TTC GTG AAG ACC TTA 944 Met Gln Ile Phe Val Lys Thr Leu 1 5ACG GGG AAG ACG ATC ACC CTA GAG GTT GAG TCT TCC GAC ACC 986Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Ser Ser Asp Thr 10 15 20ATC GAC AAT GTC AAA GCC AAG ATC CAG GAC AAG GAA GGG ATT 1028Ile Asp Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile 25 30 35CCC CCA GAC CAG CAG CGT TTG ATT TTC GCC GGA AAG CAG CTT 1070Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu 40 45 50GAG GAT GGT CGT ACT CTT GCC GAC TAC AAC ATC CAG AAG GAG 1112Glu Asp Gly Arg Thr Leu Ala Asp Tyr Asn Ile Gln Lys Glu 40 45 50TCA ACT CTC CAT CTC GTG CTC CGT CTC CGT GGT GGT GGA TCC 1154Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly Gly Ser65 70 75__________________________________________________________________________

EXAMPLE 3

Construction of Ubiquitin-lytic Peptide Fusion Plasmids With Polyubiquitin Promoter and Intron (Ubi7)

Exemplary and preferred pUC19 and pCGN1547 plasmid vectors containing a potato (Solanum tuberosum) polyubiquitin promoter and intron (Ubi7), a region coding for a ubiquitin polypeptide, and a gene coding for a lytic peptide are constructed.

To obtain the genomic clone containing a polyubiquitin promoter, intron and ubiquitin polypeptide coding region, a .lambda.FIXII potato genomic library was first prescreened using PCR as described in Example 2 above. The PCR primers are homologous to regions of the polyubiquitin cDNA (see Garbarino J., et al., Plant Molecular Biology 20: 235(1992)). A primer homologous to the 5' untranslated region of ubiquitin in the polyubiquitin cDNA and a primer complementary to the amino terminus of the ubiquitin coding region in the polyubiquitin cDNA are used. A genomic clone containing both the polyubiquitin promoter region, intron, and the polyubiquitin coding region was identified.

A chimeric gene is then constructed with a portion of the potato polyubiquitin genomic clone ligated to a lytic peptide gene, as described in Example 2. PCR is used to generate the Ubi7-ubiquitin portion of the chimeric gene. The Ubi7 promoter region includes the 1220 bp promoter and 568 bp intron upstream of the ubiquitin ATG, and the ubiquitin polypeptide coding region is 328 bp plus 6 bp of a BamHI restriction site (SEQ ID NO. 96). This plasmid is designated pUCUbi7.

A nucleotide fragment coding for the lytic peptide corresponding to the amino acid sequence SEQ ID NO. 98) is generated as described in Example 2. The resulting Ubi7 ubiquitin-lytic peptide fusion gene construct corresponds to SEQ ID NO. 95. Unlike previous cloning attempts using the CaMV35S promoter as described in the Background section, the sequence does not reveal any point mutations in the lytic peptide sub-clones. The plasmid was stable in the E. coli host and did not inhibit its growth.

The resulting pUC19 recombinant plasmid is shown in the plasmid map in FIG. 2. The sequence for the PCR insert containing the polyubiquitin promoter, intron, and the ubiquitin coding region corresponds to SEQ ID NO. 96 in Table 3 below. The sequence for the chimeric Ubi7 ubiquitin-lytic peptide fusion gene construct corresponds to SEQ ID NO. 95 in Table 3 below. This plasmid is designated as pUCUbi7-LP98.

The entire Ubi7 ubiquitin-lytic peptide fusion gene construct, including the polyadenylation site, is isolated from pUC19 as an Asp78/partial HindIII: restriction fragment (the intron has an internal HindIII site) and sub-cloned into the pCGN1547 Agrobacterium vector for use in plant transformation. This plasmid is designated pCGNUbi7-LP98.

TABLE 3__________________________________________________________________________NUCLEOTIDE SEQUENCE OF POTATO POLYUBIQUITIN PROMOTERREGION (UB17) AND UBIQUITIN CODING REGION INSERT,AND UBIQUITIN-LYTIC PRPTIDE FUSION GENE CONSTRUCT__________________________________________________________________________SEQ ID NO. 95TTTATCAATC AGATTTGAAC ATATAAATAA ATATAAATTG TCTCAATAAT 50TCTACATTAA ACTAATATTT GAAATCTCAA TTTTATGATT TTTTAAATTC 100ACTTTATATC CAAGACAATT TNCANCTTCA AAAAGTTTTA TTAAANATTT 150ACATTAGTTT TGTTGATGAG GATGACAAGA TNTTGGTCAT CAATTACATA 200TACCCAAATT GAATAGTAAG CAACTTCAAT CTTTTTCATA ATGATAATGA 250CAGACACAAN NNAAACCCAT TTATTATTCA CATTGATTGA GTTTTATATG 300CAATATAGTA ATAATAATAA TATTTCTTAT AAAGCAAGAG GTCAATTTTT 350TTTTAATTAT ACCACGTCAC TAAATTATAT TTGATAATGT AAAACAATTC 400AAATTTTACT TAAATATCAT GAAATAAACT ATTTTTATAA CCAAATTACT 450AAATTTTTCC AATAAAAAAA AGTCATTAAG AAGACATAAA ATAAATTTGA 500GGTAAANGAG TGAAGTCGAC TGACTTTTTT TTTTTTTATC ATAAGAAAAT 550AAATTATTAA CTTTAACCTA ATAAAACACT AATATAATTT CATGGAATCT 600AATACTTACC TCTTAGAAAT AAGAAAAAGT GTTTCTAATA GACCCTCAAT 650TTACATTAAA TATTTTCAAT CAAATTTAAA TAACAAATAT CAATATGAGG 700TCAATAACAA TATCAAAATA ATATGAAAAA AGAGCAATAC ATAATATAAG 750GGACGATTTA AGTGCGATTA TCAAGGTAGT ATTATATCCT AATTTGCTAA 800TATTTGNGCT CTTATATTTA AGGTCATGTT CATGATAAAC TTGAAATGCG 850CTATATTAGA GCATATATTA AAATAAAAAA ATACCTAAAA TAAAATTAAG 900TTATTTTTAG TATATATTTT TTTACATGAC CTACATTTTT CTGGGTTTTT 950CTAAAGGAGC GTGTAAGTGT CGACCTCATT CTCCTAATTT TCCCCACCAC 1000ATAAAAATTA AAAAGGAAAG GTAGCTTTTG CGTGTTGTTT TGGTACACTA 1050CACCTCATTA TTACACGTGT CCTCATATAA TTGGTTAACC CTATGAGGCG 1100GTTTCGTCTA GAGTCGGCCA TGCCATCTAT AAAATGAAGC TTTCTGCACC 1150TCATTTTTTT CATCTTCTAT CTGATTTCTA TTATAATTTC TCTCAATTGC 1200CTTCAAATTT CTCTTTAAGG TTAGAATCTT CTCTATTTTT 1240GGTTTTTGTA TGTTTAGATT CTCGAATTAG CTAATCAGGC GCTGTTATAG 1290CCCTTCCTTT TGAGTCTCTC CTCGGTTGTC TTGATGGAAA AGGCCTAACA 1340TTTGAGTTTT TTTACGTCTG GTTTGATGGA AAAGGCCTAC AATTGGCCGT 1390TTTCCCCGTT CGTTTTGATG AAAAAGCCCC TAGTTTGAGA TTTTTTTTCT 1440GTCGTTCGTT CTAAAGGTTT AAAATTAGAG TTTTTACATT TGTTTGATGA 1490AAAAGGCCTT AAATTTGAGT TTTTCCGGTT GATTTGATGA AAAAGCCCTA 1540GAATTTGTGT TTTTCCGTCG GTTTGATTCT GAAGGCCTAA AATTTGAGTT 1590TCTCCGGCTG TTTTGATGAA AAAGCCCTAA ATTTGAGTTT CTCCGGCTGT 1640TTTGATGAAA AAGCCCTAAA TTTGAAGTTT TTTCCCCGTG TTTTAGATTG 1690TTTAGGTTTT AATTCTCGAA TCAGCTAATC AGGGAGTGTG AAAGCCCTAA 1740ATTGAAGTTT TTTTCGTTGT TCTGATTGTT GTTTTTATGA ATTTGCAG 1788ATG CAG ATC TTT GTG AAA ACT CTC ACC GGA AAG ACT ATC ACC 1830Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr 1 5 10CTA GAG GTG GAA AGT TCT GAT ACA ATC GAC AAC GTT AAG GCT 1872Leu Glu Val Glu Ser Ser Asp Thr Ile Asp Asn Val Lys Ala15 20 25AAG ATC CAG GAT AAG GAA GGA ATT CCC CCG GAT CAG CAA AGG 1914Lys Ile Glu Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg 30 35 40CTT ATC TTC GCC GGA AAG CAG TTG GAG GAC GGA CGT ACT CTA 1956Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu 45 50 55GCT GAT TAC AAC ATC CAG AAG GAG TCT ACC CTC CAT TTG GTG 1998Ala Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His Leu ValCTC CGT CTA CGT GGA GGT GGA TCC GCT GTT AAA AGA GTG GGT - 2040Leu Arg Leu Arg Gly Gly Gly Ser Ala Val Lys Arg Val Gly 75 80CGT AGG TTG AAA AAG TTG GAC CGT AAG ATT GAT AGG TTA GGA 2082Arg Arg Leu Lys Lys Leu Asp Arg Lys Ile Asp Arg Leu Gly85 90 95GTT GAT TTT TGATCTAGAG CCCCGAATTT CCCCGA 2127Val Asp Phe 100SEQ ID NO 96TTTATCAATC AGATTTGAAC ATATAAATAA ATATAAATTG TCTCAATAAT 50TCTACATTAA ACTAATATTT GAAATCTCAA TTTTATGATT TTTTAAATTC 100ACTTTATATC CAAGACAATT TNCANCTTCA AAAAGTTTTA TTAAANATTT 150ACATTAGTTT TGTTGATGAG GATGACAAGA TNTTGGTCAT CAATTACATA 200TACCCAAATT GAATAGTAAG CAACTTCAAT GTTTTTCATA ATGATAATGA 250CAGACACAAN NNAAACCCAT TTATTATTCA CATTGATTGA GTTTTATATG 300CAATATAGTA ATAATAATAA TATTTCTTAT AAAGCAAGAG GTCAATTTTT 350TTTTAATTAT ACCACGTCAC TAAATTATAT TTGATAATGT AAAACAATTC 400AAATTTTACT TAAATATCAT GAAATAAACT ATTTTTATAA CCAAATTACT 450AAATTTTTCC AATAAAAAAA AGTCATTAAG AAGACATAAA ATAAATTTGA 500GGTAAANGAG TGAAGTCGAC TGACTTTTTT TTTTTTTATC ATAAGAAAAT 550AAATTATTAA CTTTAACCTA ATAAAACACT AATATAATTT CATGGAATCT 600AATACTTACC TCTTAGAAAT AAGAAAAAGT GTTTCTAATA GACCCTCAAT 650TTACATTAAA TATTTTCAAT CAAATTTAAA TAACAAATAT CAATATGAGG 700TCAATAACAA TATCAAAATA ATATGAAAAA AGAGCAATAC ATAATATAAG 750GGACGATTTA AGTGCGATTA TCAAGGTAGT ATTATATCCT AATTTGCTAA 800TATTTGNGCT CTTATATTTA AGGTCATGTT CATGATAAAC TTGAAATGCG 850CTATATTAGA GCATATATTA AAATAAAAAA ATACCTAAAA TAAAATTAAG 900TTATTTTTAG TATATATTTT TTTACATGAC CTACATTTTT CTGGGTTTTT 950CTAAAGGAGC GTGTAAGTGT CGACCTCATT CTCCTAATTT TCCCCACCAC 1000ATAAAAATTA AAAAGGAAAG GTAGCTTTTG CGTGTTGTTT TGGTACACTA 1050CACCTCATTA TTACACGTGT CCTCATATAA TTGGTTAACC CTATGAGGCG 1100GTTTCGTCTA GAGTCGGCCA TGCCATCTAT AAAATGAAGC TTTCTGCACC 1150TCATTTTTTT CATCTTCTAT CTGATTTCTA TTATAATTTC TCTCAATTGC 1200CTTCAAATTT CTCTTTAAGG TTAGAATCTT CTCTATTTTT 1240GGTTTTTGTA TGTTTAGATT CTCGAATTAG CTAATCAGGC GCTGTTATAG 1290CCCTTCCTTT TGAGTCTCTC CTCGGTTGTC TTGATGGAAA AGGCCTAACA 1340TTTGAGTTTT TTTACGTCTG GTTTGATGGA AAAGGCCTAC AATTGGCCGT 1390TTTCCCCGTT CGTTTTGATG AAAAAGCCCC TAGTTTGAGA TTTTTTTTCT 1440GTCGTTCGTT CTAAAGGTTT AAAATTAGAG TTTTTACATT TGTTTGATGA 1490AAAAGGCCTT AAATTTGAGT TTTTCCGGTT GATTTGATGA AAAAGCCCTA 1540GAATTTGTGT TTTTCCGTCG GTTTGATTCT GAAGGCCTAA AATTTGAGTT 1590TCTCCGGCTG TTTTGATGAA AAAGCCCTAA ATTTGAGTTT CTCCGGCTGT 1640TTTGATGAAA AAGCCCTAAA TTTGAAGTTT TTTCCCCGTG TTTTAGATTG 1690TTTAGGTTTT AATTCTCGAA TCAGCTAATC AGGGAGTGTG AAAGCCCTAA 1740ATTGAAGTTT TTTTCGTTGT TCTGATTGTT GTTTTTATGA ATTTGCAG 1788ATG CAG ATC TTT GTG AAA ACT CTC ACC GGA AAG ACT ATC ACC 1830Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr 1 5 10CTA GAG GTG GAA AGT TCT GAT ACA ATC GAC AAC GTT AAG GCT 1872Leu Glu Val Glu Ser Ser Asp Thr Ile Asp Asn Val Lys Ala15 20 25AAG ATC CAG GAT AAG GAA GGA ATT CCC CCG GAT CAG CAA AGG 1914Lys Ile Glu Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg 30 35 40CTT ATC TTC GCC GGA AAG CAG TTG GAG GAC GGA CGT ACT CTA 1956Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu 45 50 55GCT GAT TAC AAC ATC CAG AAG GAG TCT ACC CTC CAT TTG GTG 1998Ala Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His Leu Val 60 65 70CTC CGT CTA CGT GGA GGT GGA TCC 2022Leu Arg Leu Arg Gly Gly Gly Ser 75__________________________________________________________________________

EXAMPLE 4

Construction of Ubiquitin-Lytic Peptide Fusion Gene Plasmid Vectors

pUC19 and pCGN1547 plasmid vectors containing a potato (Solanum tuberosum) Ubi3 promoter, a region coding for a ubiquitin polypeptide, and a gene coding for a lytic peptide are constructed according to Example 2. Each plasmid respectively contains one lytic peptide nucleotide sequence coding for an amino acid sequence corresponding to SEQ ID NO. 1, 7, 15, 21, 30, 39, 43, 52, 83, 86, 88, 90, and 91. The resultant pUC19 Ubi3 ubiquitin-lytic peptide recombinant plasmids are designated as follows: pUCUbi3-LP1, pUCUbi3-LP7, pUCUbi3-LP15, pUCUbi3-LP21, pUCUbi3-LP30, pUCUbi3-LP39, pUCUbi3-LP43, pUCUbi3-LP52, pUCUbi3-LP83, pUCUbi3-LP86, pUCUbi3-LP88, pUCUbi3-LP90, and pUCUbi3-LP91. The resultant pCGN1547 Ubi3 ubiquitin-lytic peptide recombinant plasmids are designated as follows: pCGNUbi3-LP1, pCGNUbi3-LP7, pCGNUbi3-LP15, pCGNUbi3-LP21, pCGNUbi3-LP30, pCGNUbi3-LP39, pCGNUbi3-LP43, pCGNUbi3-LP52, pCGNUbi3-LP83, pCGNUbi3-LP86, pCGNUbi3-LP88, pCGNUbi3-LP90, and pCGNUbi3-LP91.

pUC19 and pCGN1547 plasmid vectors containing a potato (Solanum tuberosum) Ubi7 promoter and intron, a region coding for a ubiquitin polypeptide, and a gene coding for a lytic peptide are constructed according to Example 3. Each plasmid respectively contains one lytic peptide nucleotide sequence coding for an amino acid sequence corresponding to SEQ ID NO. 1, 7, 15, 21, 30, 39, 43, 52, 83, 86, 88, 90, and 91. The resultant pUC19 Ubi7 ubiquitin-lytic peptide recombinant plasmids are designated as follows: pUCUbi7-LP1, pUCUbi7-LP7, pUCUbi7-LP15, pUCUbi7-LP21, pUCUbi7-LP30, pUCUbi7-P39, pUCUbi7-LP43, pUCUbi7-LP52, pUCUbi7-LP83, pUCUbi7-LP86, pUCUbi7-LP88, pUCUbi7-LP90, and pUCUbi7-LP91. The resultant pCGN1547 Ubi7 ubiquitin-lytic peptide recombinant plasmids are designated as follows: pCGNUbi7-LP1, pCGNUbi7-LP7, pCGNUbi7-LP15, pCGNUbi7,-LP21, pCGNUbi7-LP30, pCGNUbi7-LP39, pCGNUbi7-LP43, pCGNUbi7-LP52, pCGNUbi7-LP83, pCGNUbi7-LP86, pCGNUbi7-LP88, pCGNUbi7-LP90, and pCGNUbi7-LP91.

EXAMPLE 5

Construction of GUS-Ubiquitin Fusion Gene Recombinant DNA Molecules and Ubiquitin Promoter-GUS Recombinant DNA Molecules

Two chimeric genes containing a .beta.-glucuronidase (GUS) reporter gene and the Ubi3 promoter were constructed in-pCGN1547 plasmid vectors according to Garbarino, J., and Belknap, W., Plant Molecular Biology 24: 119 (1994), hereby incorporated by reference in its entirety. The first vector contains the 920 bp Ubi3 promoter ligated to the GUS gene, and expresses the GUS protein. This plasmid is designated pCGNUbi3-GUS. The second vector contains the 920 bp Ubi3 promoter and 228 bp ubiquitin coding region ligated in frame to the GUS gene. This plasmid expresses a ubiquitin-GUS fusion polypeptide. This plasmid is designated pCGNUbi3-GUSf.

Two chimeric genes containing a .beta.-glucuronidase (GUS) reporter gene and the Ubi7 promoter minus the intron region were constructed in pCGN1547 plasmid vectors using PCR, as described in Example 3 and in Garbarino, J., and Belknap, W., Plant Molecular Biology 24: 119 (1994). The first vector contains a 1156 bp Ubi7 promoter region insert, including she 5' untranslated region of ubiquitin, ligated to the GUS gene. This plasmid does not contain the Ubi7 intron and expresses the GUS protein. This plasmid is designated pCGNUbi7-GUS. The second vector contains the 1156 Ubi7 ubiquitin promoter from pCGNUbi7-GUS and the 228 bp ubiquitin coding region fused in frame to the GUS reporter gene. This plasmid expresses a ubiquitin-GUS fusion polypeptide and is designated pCGNUbi7-GUSf.

EXAMPLE 6

Plant Transformation and GUS Gene Expression

The chimeric plasmids pCGNUbi3-GUS, pCGNUbi3-GUSf, pCGNUbi7-GUS, and pCGNUbi7-GUSf from Example 5 are introduced into the potato (Solanum tuberosum) using Agrobacterium mediated transformation according to Garbarino, J., and Belknap, W. Plant Molecular Biology 24:119 (1994). The strain of Agrobacterium tumefaciens used for transformation (PC2760, see An, G., et al., EMBO J. 4: 277 (1985)) harbors the disarmed Ti plasmid pAL4404 (see Hoekema, A., et al., Nature 303: 179 (1983). Plant transformation is carried out as previously described in Synder, G. W., et al., Plant Cell Rep 12:324 (1993), except that 1 mg/l silver thiosulfate is added to the stage II transformation medium (see Chang, H. H., et al., Bot Bull Acad Sci 32: 63 (1991).

Expression of the ubiquitin-GUS fusion polypeptide and MRNA products and the GUS protein alone is examined by northern and western analysis, as described in Garbarino J., and Belknap, W., Plant Molecular Biology 24: 119 (1994). GUS protein expression is examined in the transgenic plants using western analysis. Although there is a wide range of activity among individual clones, the ubiquitin-GUS fusion polypeptide containing plants generally give 5-10 fold higher expression than the plants containing GUS protein alone. This higher level of protein expression Corresponds to similarly elevated mRNA transcription levels for the ubiquitin-GUS fusion constructs, as shown by northern analysis (described in Garbarino et al., Plant Molecular Biology 24: 119 (1994)). Western analysis also shows that the ubiquitin-GUS fusion polypeptide was appropriately processed by endogenous ubiquitin hydrolases co produce free GUS protein.

GUS protein activity is measured as described by Jefferson, R. A., et al., EMBO J. 6: 3901 (1987). Table 4 below shows a comparison of the GUS activities in plants transformed with pCGNUbi3-GUS (ubi-) and plants transformed with pCGNUbi3-GUSf (ubi+). The activity is measured in nmoles methyl umbelliferon (MU) per minute per milligram of protein. Methyl umbelliferon is the fluorescent product of the GUS enzymatic reaction.

TABLE 4______________________________________COMPARISON OF GUS PROTEIN ACTIVITY IN PLANTSTRANSFORMED WITH THE UBI3 PROMOTER WITH (+UBI)AND WITHOUT (-UBI) UBIQUITIN POLYPEPTIDE FUSIONGUS Activity (nmoles MU/min/mg protein) Leaf SenescentConstruct Meristem 2nd Leaf 5th Leaf Leaf Tuber______________________________________3.2 - ubi 6.31 .+-. 2.51 .+-. 1.79 .+-. 5.42 .+-. 3.26 .+-. 0.74 0.52 0.22 1.24 0.278.1 - ubi 25.8 .+-. 9.98 .+-. 6.34 .+-. 19.20 .+-. 14.2 .+-. 2.08 2.10 1.00 6.11 1.63.5 + ubi 94.8 .+-. 60.3 .+-. 32.7 .+-. 50.1 .+-. 37.6 .+-. 12.6 25.1 8.71 11.6 10.49.8 + ubi 33.3 .+-. 18.9 .+-. 9.74 .+-. 22.7 .+-. 20.7 .+-. 0.5 2.75 0.99 3.57 3.45______________________________________

EXAMPLE 7

Plant Transformation and Ubiquitin-Lytic Peptide Gene Expression

The chimeric plasmids pCGNUbi3-LP98 from Example 2 and pCGNUbi7-LP98 from Example 3 are introduced into the potato (Solanum tuberosum) using Agrobacterium mediated transformation according to Garbarino, J., and Belknap, W. Plant Molecular Biology 24:119 (1994). The strain of Agrobacterium tumefaciens used for transformation (PC2760, see An, G., et al., 3EMBO J. 4: 277 (1985)) harbors the disarmed Ti plasmid pAL4404 (see Hoekema, A., et al., Nature 303: 179 (1983). Plant transformation is carried out as previously described in Synder, G. W., et al., Plant Cell Rep 12:324 (1993), except that 1 mg/l silver thiosulfate is added to the stage II transformation medium (see Chang, H. H., et al., Bot Bull Acad Sci 32: 63 (1991).

Expression of the ubiquitin-lytic peptide fusion polypeptide and mRNA products is examined by northern and western analysis, in Garbarino J., and Belknap, W., Plant Molecular Biology 24: 119 (1994). Northern analysis shows that ubiquitin-lytic peptide mRNA is transcribed from the gene construct in the transgenic plants. Western analysis shows that the ubiquitin-lytic peptide fusion polypeptide is appropriately processed by endogenous ubiquitin in hydrolases to produce free lytic peptide.

EXAMPLE 8

Cloned Ubi3/Ubi7 Promoter Activity

mRNA expression from the cloned Ubi3 promoter was examined before and after wounding to determine if the cloned Ubi3 promoter is wound inducible in transformed plants (see Garbarino, J. and Belknap, W., Plant Molecular Biology 24:119 (1994)). Northern analysis comparing endogenous Ubi3 mRNA expression levels to pCGNUbi3-GUS and pCGNUbi3-GUSf mRNA expression levels in transformed plants (see Example 5) shows that while the endogenous Ubi3 mRNA transcription increases upon wounding, transcription from the recombinant Ubi3 plasmids does not. Thus the recombinant Ubi3 promoter does not have the wound inducible characteristic of the endogenous Ubi3 promoter. This result suggests that the 920 bp of upstream sequence cloned in the Ubi3 genomic clone is not sufficient to obtain wound-dependent activation of the promoter. The promoter instead is constitutive, however, it still demonstrates developmental regulation, as shown in Table 4 above.

In contrast, the cloned TUi-b promoter retains its wound-dependent induction. Northern analysis comparing the endogenous Ubi7 mRNA expression levels to the expression levels from pCGNUbi7-GUS and pCGNUbi7-GUSf in transformed plants (see Example 5) shows that both the endogenous and the cloned Ubi7 promoter have wound-dependent activation.

DEPOSIT INFORMATION

E. coli cultures, each respectively transformed with pUCUbi7-LP98 (Local Accession No. PBT-0273), pUCUbi3-LP98 (Local Accession No. PBT-0276), pUCUbi7 (Local Accession No. PBT-0277), and pUCUbi3 (Local Accession No. PBT-0234) were deposited in the Agricultural Research Service Culture Collection (NRRL). The depository is located at located at 1815 North University Street, Peoria, Ill.,

__________________________________________________________________________# SEQUENCE LISTING- (1) GENERAL INFORMATION:- (iii) NUMBER OF SEQUENCES: 98- (2) INFORMATION FOR SEQ ID NO: 1:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#1: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Val Ala Val Lys Ala Val Lys Lys Al - #a Val Lys Lys Val Lys# 15- Lys Ala Val Lys Lys Ala Val Lys Lys Lys Ly - #s# 25- (2) INFORMATION FOR SEQ ID NO: 2:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#2: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Val Ala Val Lys Ala Val Ala Val Ly - #s Ala Val Lys Lys Ala# 15- Val Lys Lys Val Lys Lys Ala Val Lys Lys Al - #a Val Lys Lys Lys Lys# 30- (2) INFORMATION FOR SEQ ID NO: 3:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#3: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Val Ala Val Lys Ala Val Ala Val Ly - #s Ala Val Ala Val Lys# 15- Ala Val Lys Lys Ala Val Lys Lys Val Lys Ly - #s Ala Val Lys Lys Ala# 305- Val Lys Lys Lys Lys 35- (2) INFORMATION FOR SEQ ID NO: 4:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#4: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Val Ala Val Lys Ala Val Lys Lys Al - #a Val Lys Lys Val Lys# 15- Lys Ala Val Lys Lys Ala Val 20- (2) INFORMATION FOR SEQ ID NO: 5:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#5: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Val Ala Val Lys Ala Val Ala Val Ly - #s Ala Val Lys Lys Ala# 15- Val Lys Lys Val Lys Lys Ala Val Lys Lys Al - #a Val# 25- (2) INFORMATION FOR SEQ ID NO: 6:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#6: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Val Ala Val Lys Ala Val Ala Val Ly - #s Ala Val Ala Val Lys# 15- Ala Val Lys Lys Ala Val Lys Lys Val Lys Ly - #s Ala Val Lys Lys Ala# 305- Val- (2) INFORMATION FOR SEQ ID NO: 7:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#7: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Val Gly Leu Arg Ala Ile Lys Arg Al - #a Leu Lys Lys Leu Arg# 15- Arg Gly Val Arg Lys Val Ala Lys Arg Lys Ar - #g# 25- (2) INFORMATION FOR SEQ ID NO: 8:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#8: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Val Gly Leu Arg Ala Ile Lys Arg Al - #a Leu Lys Lys Leu Arg# 15- Arg Gly Val Arg Lys Val Ala 20- (2) INFORMATION FOR SEQ ID NO: 9:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#9: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Arg Lys Arg Ala Val Lys Arg Val Gly Ar - #g Arg Leu Lys Lys Leu# 15- Ala Arg Lys Ile Ala Arg Leu Gly Val Ala Ph - #e# 25- (2) INFORMATION FOR SEQ ID NO: 10:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#10: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Ala Val Lys Arg Val Gly Arg Arg Leu Lys Ly - #s Leu Ala Arg Lys Ile# 15- Ala Arg Leu Gly Val Ala Phe 20- (2) INFORMATION FOR SEQ ID NO: 11:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#11: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Val Gly Leu Arg Ala Ile Lys Arg Al - #a Leu Lys Lys Leu Arg# 15- Arg Gly Val Arg Lys Val Ala Lys Arg Lys Ar - #g Lys Lys Asp Leu# 305- (2) INFORMATION FOR SEQ ID NO: 12:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#12: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Val Gly Leu Arg Ala Ile Lys Arg Al - #a Leu Lys Lys Leu Arg# 15- Arg Gly Val Arg Lys Val Ala Lys Asp Leu# 25- (2) INFORMATION FOR SEQ ID NO: 13:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#13: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Arg Lys Arg Ala Val Lys Arg Val Gly Ar - #g Arg Leu Lys Lys Leu# 15- Ala Arg Lys Ile Ala Arg Leu Gly Val Ala Ph - #e Lys Asp Leu# 30- (2) INFORMATION FOR SEQ ID NO: 14:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#14: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Ala Val Lys Arg Val Gly Arg Arg Leu Lys Ly - #s Leu Ala Arg Lys Ile# 15- Ala Arg Leu Gly Val Ala Phe Lys Asp Leu# 25- (2) INFORMATION FOR SEQ ID NO: 15:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#15: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Lys Lys Lys Phe Val Lys Lys Val Ala Ly - #s Lys Val Lys Lys Val# 15- Ala Lys Lys Val Ala Lys Val Ala Val Ala Va - #l# 25- (2) INFORMATION FOR SEQ ID NO: 16:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#16: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Lys Lys Lys Phe Val Lys Lys Val Ala Ly - #s Lys Val Lys Lys Val# 15- Ala Lys Lys Val Ala Lys Val Ala Val Ala Ly - #s Val Ala Val Ala Val# 305- (2) INFORMATION FOR SEQ ID NO: 17:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#17: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Lys Lys Lys Phe Val Lys Lys Val Ala Ly - #s Lys Val Lys Lys Val# 15- Ala Lys Lys Val Ala Lys Val Ala Val Ala Ly - #s Val Ala Val Ala Lys# 30- Val Ala Val Ala Val 35- (2) INFORMATION FOR SEQ ID NO: 18:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#18: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Val Lys Lys Val Ala Lys Lys Val Lys Ly - #s Val Ala Lys Lys Val# 15- Ala Lys Val Ala Val Ala Val 20- (2) INFORMATION FOR SEQ ID NO: 19:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#19: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Val Lys Lys Val Ala Lys Lys Val Lys Ly - #s Val Ala Lys Lys Val# 15- Ala Lys Val Ala Val Ala Lys Val Ala Val Al - #a Val# 25- (2) INFORMATION FOR SEQ ID NO: 20:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#20: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Val Lys Lys Val Ala Lys Lys Val Lys Ly - #s Val Ala Lys Lys Val# 15- Ala Lys Val Ala Val Ala Lys Val Ala Val Al - #a Lys Val Ala Val Ala# 30- Val- (2) INFORMATION FOR SEQ ID NO: 21:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#21: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Lys Lys Lys Phe Val Lys Lys Val Ala Ly - #s Val Ala Lys Lys Val# 15- Ala Lys Val Ala Lys Lys Val Ala Lys Lys Va - #l# 25- (2) INFORMATION FOR SEQ ID NO: 22:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#22: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Lys Lys Lys Phe Val Lys Lys Val Ala Ly - #s Val Ala Lys Lys Val# 15- Ala Lys Val Ala Lys Lys Val Ala Lys Lys Va - #l Ala Lys Lys Val Ala# 30- (2) INFORMATION FOR SEQ ID NO: 23:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#23: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Lys Lys Lys Phe Val Lys Lys Val Ala Ly - #s Val Ala Lys Lys Val# 15- Ala Lys Val Ala Lys Lys Val Ala Lys Lys Va - #l Ala Lys Lys Val Ala# 305- Lys Val Ala Lys Lys 35- (2) INFORMATION FOR SEQ ID NO: 24:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#24: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Val Lys Lys Val Ala Lys Val Ala Lys Ly - #s Val Ala Lys Val Ala# 15- Lys Lys Val Ala Lys Lys Val 20- (2) INFORMATION FOR SEQ ID NO: 25:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#25: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Val Lys Lys Val Ala Lys Val Ala Lys Ly - #s Val Ala Lys Val Ala# 15- Lys Lys Val Ala Lys Lys Val Ala Lys Lys Va - #l Ala# 25- (2) INFORMATION FOR SEQ ID NO: 26:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#26: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Val Lys Lys Val Ala Lys Val Ala Lys Ly - #s Val Ala Lys Val Ala# 15- Lys Lys Val Ala Lys Lys Val Ala Lys Lys Va - #l Ala Lys Val Ala Lys# 305- Lys- (2) INFORMATION FOR SEQ ID NO: 27:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#27: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Val Lys Lys Val Ala Lys Val Ala Lys Ly - #s Val Ala Lys Val Ala# 15- Lys Lys Val Ala Lys Lys Val Lys Lys Lys Ly - #s# 25- (2) INFORMATION FOR SEQ ID NO: 28:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#28: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Val Lys Lys Val Ala Lys Val Ala Lys Ly - #s Val Ala Lys Val Ala# 15- Lys Lys Val Ala Lys Lys Val Ala Lys Lys Va - #l Ala Lys Lys Lys Lys# 305- (2) INFORMATION FOR SEQ ID NO: 29:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#29: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Val Lys Lys Val Ala Lys Val Ala Lys Ly - #s Val Ala Lys Val Ala# 15- Lys Lys Val Ala Lys Lys Val Ala Lys Lys Va - #l Ala Lys Val Ala Lys# 30- Lys Lys Lys Lys Lys 35- (2) INFORMATION FOR SEQ ID NO: 30:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#30: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Lys Val Lys Ala Lys Val Lys Ala Lys Va - #l Lys Lys Lys Lys Lys# 15- (2) INFORMATION FOR SEQ ID NO: 31:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#31: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Lys Val Lys Ala Lys Val Lys Ala Lys Va - #l Lys Ala Lys Val Lys# 15- Ala Lys Lys Lys Lys 20- (2) INFORMATION FOR SEQ ID NO: 32:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#32: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Lys Val Lys Ala Lys Val Lys Ala Lys Va - #l Lys Ala Lys Val Lys# 15- Ala Lys Val Lys Ala Lys Val Lys Lys Lys Ly - #s# 25- (2) INFORMATION FOR SEQ ID NO: 33:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#33: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Lys Val Lys Ala Lys Val Lys Ala Lys Va - #l Lys# 10- (2) INFORMATION FOR SEQ ID NO: 34:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#34: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Lys Val Lys Ala Lys Val Lys Ala Lys Va - #l Lys Ala Lys Val Lys# 15- Ala- (2) INFORMATION FOR SEQ ID NO: 35:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#35: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Lys Val Lys Ala Lys Val Lys Ala Lys Va - #l Lys Ala Lys Val Lys# 15- Ala Lys Val Lys Ala Lys Val 20- (2) INFORMATION FOR SEQ ID NO: 36:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#36: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Lys Lys Lys Phe Lys Val Lys Ala Lys Va - #l Lys Ala Lys Val Lys# 15- (2) INFORMATION FOR SEQ ID NO: 37:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#37: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Lys Lys Lys Phe Lys Val Lys Ala Lys Va - #l Lys Ala Lys Val Lys# 15- Ala Lys Val Lys Ala 20- (2) INFORMATION FOR SEQ ID NO: 38:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#38: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Lys Lys Lys Phe Lys Val Lys Ala Lys Va - #l Lys Ala Lys Val Lys# 15- Ala Lys Val Lys Ala Lys Val Lys Ala Lys Va - #l# 25- (2) INFORMATION FOR SEQ ID NO: 39:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#39: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Lys Lys Val Lys Lys Val Ala Lys Lys Va - #l Cys Lys Cys Val Lys# 15- Lys Ala Val Lys Lys Val Lys Lys Phe# 25- (2) INFORMATION FOR SEQ ID NO: 40:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#40: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Val Ala Val Lys Ala Val Lys Lys Al - #a Val Lys Lys Val Lys# 15- Lys Ala Val Lys Lys Ala Val Cys Cys Cys Cy - #s# 25- (2) INFORMATION FOR SEQ ID NO: 41:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#41: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Cys Cys Cys Cys Phe Val Lys Lys Val Ala Ly - #s Lys Val Lys Lys Val# 15- Ala Lys Lys Val Ala Lys Val Ala Val Ala Va - #l# 25- (2) INFORMATION FOR SEQ ID NO: 42:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#42: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Val Ala Val Lys Ala Val Lys Lys Al - #a Val Lys Lys Val Lys# 15- Lys Ala Val Lys Lys Ala Val Ser Ser Ser Se - #r# 25- (2) INFORMATION FOR SEQ ID NO: 43:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#43: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Ser Ser Ser Ser Phe Val Lys Lys Val Ala Ly - #s Lys Val Lys Lys Val# 15- Ala Lys Lys Val Ala Lys Val Ala Val Ala Va - #l# 25- (2) INFORMATION FOR SEQ ID NO: 44:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#44: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Leu Ala Leu Lys Ala Leu Lys Lys Al - #a Leu Lys Lys Leu Lys# 15- Lys Ala Leu Lys Lys Ala Leu 20- (2) INFORMATION FOR SEQ ID NO: 45:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#45: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Leu Ala Lys Lys Leu Ala Lys Lys Leu Lys Ly - #s Leu Ala Lys Lys Leu# 150- Ala Lys Leu Ala Leu Ala Phe 20- (2) INFORMATION FOR SEQ ID NO: 46:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#46: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Phe Ala Phe Lys Ala Phe Lys Lys Al - #a Phe Lys Lys Phe Lys# 150- Lys Ala Phe Lys Lys Ala Phe 20- (2) INFORMATION FOR SEQ ID NO: 47:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#47: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Ile Ala Ile Lys Ala Ile Lys Lys Al - #a Ile Lys Lys Ile Lys# 150- Lys Ala Ile Lys Lys Ala Ile 20- (2) INFORMATION FOR SEQ ID NO: 48:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#48: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Lys Lys Phe Ala Lys Lys Phe Lys Ly - #s Phe Ala Lys Lys Phe# 150- Ala Lys Phe Ala Phe Ala Phe 20- (2) INFORMATION FOR SEQ ID NO: 49:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#49: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Lys Arg Leu Ala Lys Ile Lys Val Leu Ar - #g Leu Ala Lys Ile Lys# 150- Arg- (2) INFORMATION FOR SEQ ID NO: 50:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#50: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Leu Lys Leu Ala Val Lys Leu Val Gly Le - #u Leu Arg Lys Lys Arg# 150- Ala Leu Lys Ile Ala Leu Arg Gly Val Ala Ly - #s Arg Ala Gly Arg Leu# 30- Ala Val Arg Lys Phe 35- (2) INFORMATION FOR SEQ ID NO: 51:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#51: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Arg Ala Arg Lys Ala Arg Lys Lys Al - #a Arg Lys Lys Arg Lys# 150- Lys Ala Arg Lys Lys Ala Arg Lys Asp Arg# 25- (2) INFORMATION FOR SEQ ID NO: 52:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#52: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Val Ala Val Cys Ala Val Cys Cys Al - #a Val Cys Cys Val Cys# 150- Cys Ala Val Cys Cys Ala Val 20- (2) INFORMATION FOR SEQ ID NO: 53:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#53: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Val Ala Val Ser Ala Val Ser Ser Al - #a Val Ser Ser Val Ser# 150- Ser Ala Val Ser Ser Ala Val 20- (2) INFORMATION FOR SEQ ID NO: 54:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#54: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Val Ala Val Ser Ala Val Ser Ser Al - #a Val Ser Ser Val Ser# 150- Ser Ala Val Ser Ser Ala Val Ser Ser Ser Se - #r# 25- (2) INFORMATION FOR SEQ ID NO: 55:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#55: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Lys Lys Phe Ala Lys Lys Phe Lys Ly - #s Phe Ala Lys Lys Phe# 150- Ala Lys Phe Ala Phe Ala Phe Lys Lys Lys Ly - #s# 25- (2) INFORMATION FOR SEQ ID NO: 56:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#56: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Lys Lys Lys Phe Ala Lys Lys Phe Ala Ly - #s Lys Phe Lys Lys Phe# 150- Ala Lys Lys Phe Ala Lys Phe Ala Phe Ala Ph - #e# 25- (2) INFORMATION FOR SEQ ID NO: 57:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#57: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Arg Lys Phe Leu Lys Arg Phe Lys Ly - #s Phe Val Arg Lys Phe# 150- Ile Arg Phe Ala Phe Leu Phe 20- (2) INFORMATION FOR SEQ ID NO: 58:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#58: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Ala Arg Lys Phe Leu Lys Arg Phe Lys Ly - #s Phe Val Arg Lys Phe# 150- Ile Arg Phe Ala Phe Leu Phe Lys Arg Lys Ar - #g# 25- (2) INFORMATION FOR SEQ ID NO: 59:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#59: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Arg Lys Arg Phe Ala Arg Lys Phe Leu Ly - #s Arg Phe Lys Lys Phe# 150- Val Arg Lys Phe Ile Arg Phe Ala Phe Leu Ph - #e# 25- (2) INFORMATION FOR SEQ ID NO: 60:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#60: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Ile Ala Lys Lys Ile Ala Lys Lys Ile Lys Ly - #s Ile Ala Lys Lys Ile# 150- Ala Lys Ile Ala Ile Ala Ile 20- (2) INFORMATION FOR SEQ ID NO: 61:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#61: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Ile Ala Lys Lys Ile Ala Lys Lys Ile Lys Ly - #s Ile Ala Lys Lys Ile# 150- Ala Lys Ile Ala Ile Ala Ile Lys Lys Lys Ly - #s# 25- (2) INFORMATION FOR SEQ ID NO: 62:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#62: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Lys Lys Lys Ile Ala Lys Lys Ile Ala Ly - #s Lys Ile Lys Lys Ile# 150- Ala Lys Lys Ile Ala Lys Ile Ala Ile Ala Il - #e# 25- (2) INFORMATION FOR SEQ ID NO: 63:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#63: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Ile Ala Arg Lys Ile Leu Lys Arg Ile Lys Ly - #s Ile Val Arg Lys Phe# 150- Ile Arg Ile Ala Ile Leu Ile 20- (2) INFORMATION FOR SEQ ID NO: 64:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#64: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Ile Ala Arg Lys Ile Leu Lys Arg Ile Lys Ly - #s Ile Val Arg Lys Phe# 150- Ile Arg Ile Ala Ile Leu Ile Lys Arg Lys Ar - #g# 25- (2) INFORMATION FOR SEQ ID NO: 65:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#65: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Arg Lys Arg Ile Ala Arg Lys Ile Leu Ly - #s Arg Ile Lys Lys Ile# 150- Val Arg Lys Phe Ile Arg Ile Ala Ile Leu Il - #e# 25- (2) INFORMATION FOR SEQ ID NO: 66:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#66: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Le - #u Arg Ala Lys Ile Lys# 150- Leu- (2) INFORMATION FOR SEQ ID NO: 67:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#67: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Arg Lys Arg Phe Lys Leu Arg Ala Lys Il - #e Lys Val Arg Leu Arg# 150- Ala Lys Ile Lys Leu 20- (2) INFORMATION FOR SEQ ID NO: 68:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#68: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Le - #u Arg Ala Lys Ile Lys# 150- Leu Lys Arg Lys Arg 20- (2) INFORMATION FOR SEQ ID NO: 69:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#69: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Le - #u Arg Ala Lys Ile Lys# 150- Leu Arg Val Lys Leu Lys Ile 20- (2) INFORMATION FOR SEQ ID NO: 70:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#70: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Le - #u Arg Ala Lys Ile Lys# 150- Leu Arg Val Lys Leu Lys Ile Lys Arg Lys Ar - #g# 25- (2) INFORMATION FOR SEQ ID NO: 71:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#71: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Arg Lys Arg Phe Lys Leu Arg Ala Lys Il - #e Lys Val Arg Leu Arg# 150- Ala Lys Ile Lys Leu Arg Val Lys Leu Lys Il - #e# 25- (2) INFORMATION FOR SEQ ID NO: 72:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#72: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Le - #u Arg Ala Lys Ile Lys# 150- Leu Arg Val Lys Leu Lys Ile Arg Ala Arg Il - #e Lys Leu# 25- (2) INFORMATION FOR SEQ ID NO: 73:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#73: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Le - #u Arg Ala Lys Ile Lys# 150- Leu Arg Val Lys Leu Lys Ile Arg Ala Arg Il - #e Lys Leu Lys Arg Lys# 30- Arg- (2) INFORMATION FOR SEQ ID NO: 74:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#74: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Arg Lys Arg Phe Lys Leu Arg Ala Lys Il - #e Lys Val Arg Leu Arg# 150- Ala Lys Ile Lys Leu Arg Val Lys Leu Lys Il - #e Arg Ala Arg Ile Lys# 30- Leu- (2) INFORMATION FOR SEQ ID NO: 75:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#75: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Le - #u Arg Ala Lys Ile Lys# 150- Leu Val Phe Ala Ile Leu Leu 20- (2) INFORMATION FOR SEQ ID NO: 76:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#76: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Phe Lys Leu Arg Ala Lys Ile Lys Val Arg Le - #u Arg Ala Lys Ile Lys# 150- Leu Val Phe Ala Ile Leu Leu Lys Arg Lys Ar - #g# 25- (2) INFORMATION FOR SEQ ID NO: 77:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#77: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Arg Lys Arg Phe Lys Leu Arg Ala Lys Il - #e Lys Val Arg Leu Arg# 150- Ala Lys Ile Lys Leu Val Phe Ala Ile Leu Le - #u# 25- (2) INFORMATION FOR SEQ ID NO: 78:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#78: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Val Phe Ala Ile Leu Leu Phe Lys Leu Arg Al - #a Lys Ile Lys Val Arg# 150- Leu Arg Ala Lys Ile Lys Leu 20- (2) INFORMATION FOR SEQ ID NO: 79:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#79: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Val Phe Ala Ile Leu Leu Phe Lys Leu Arg Al - #a Lys Ile Lys Val Arg# 150- Leu Arg Ala Lys Ile Lys Leu Lys Arg Lys Ar - #g# 25- (2) INFORMATION FOR SEQ ID NO: 80:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#80: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Arg Lys Arg Val Phe Ala Ile Leu Leu Ph - #e Lys Leu Arg Ala Lys# 150- Ile Lys Val Arg Leu Arg Ala Lys Ile Lys Le - #u# 25- (2) INFORMATION FOR SEQ ID NO: 81:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#81: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Val Gly Glu Cys Val Arg Gly Arg Cys Pro Se - #r Gly Met Cys Cys Ser# 150- Gln Phe Gly Tyr Cys Gly Lys Gly Pro Lys Ty - #r Cys Gly# 25- (2) INFORMATION FOR SEQ ID NO: 82:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#82: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Val Gly Glu Cys Val Arg Gly Arg Cys Pro Se - #r Gly Met Cys Cys Ser# 150- Gln Phe Gly Tyr Cys Gly Lys Gly Pro Lys Ty - #r Cys Gly Arg# 30- (2) INFORMATION FOR SEQ ID NO: 83:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#83: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Leu Gly Asp Cys Leu Lys Gly Lys Cys Pro Se - #r Gly Met Cys Cys Ser# 150- Asn Tyr Gly Phe Cys Gly Arg Gly Pro Arg Ph - #e Cys Gly Lys# 30- (2) INFORMATION FOR SEQ ID NO: 84:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#84: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Gln Cys Ile Gly Asn Gly Gly Arg Cys Asn Gl - #u Asn Val Gly Pro Pro# 150- Tyr Cys Cys Ser Gly Phe Cys Leu Arg Gln Pr - #o Gly Gln Gly Tyr Gly# 30- Tyr Cys Lys Asn Arg 35- (2) INFORMATION FOR SEQ ID NO: 85:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#85: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Cys Ile Gly Asn Gly Gly Arg Cys Asn Glu As - #n Val Gly Pro Pro Tyr# 150- Cys Cys Ser Gly Phe Cys Leu Arg Gln Pro As - #n Gln Gly Tyr Gly Val# 30- Cys Arg Asn Arg 35- (2) INFORMATION FOR SEQ ID NO: 86:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#86: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Cys Ile Gly Gln Gly Gly Lys Cys Gln Asp Gl - #n Leu Gly Pro Pro Phe# 150- Cys Cys Ser Gly Tyr Cys Val Lys Asn Pro Gl - #n Asn Gly Phe Gly Leu# 30- Cys Lys Gln Lys 35- (2) INFORMATION FOR SEQ ID NO: 87:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 44 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#87: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Gln Lys Leu Cys Glu Arg Pro Ser Gly Thr Tr - #p Ser Gly Val Cys Gly# 150- Asn Asn Asn Ala Cys Lys Asn Gln Cys Ile As - #n Leu Glu Lys Ala Arg# 30- His Gly Ser Cys Asn Tyr Val Phe Pro Ala Hi - #s Lys# 40- (2) INFORMATION FOR SEQ ID NO: 88:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 44 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#88: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Gln Arg Val Cys Asp Lys Pro Ser Gly Thr Tr - #p Ser Gly Leu Cys Gly# 150- Asn Asn Asn Ala Cys Arg Gln Asn Cys Ile Gl - #n Val Asp Arg Ala Lys# 30- Lys Gly Ser Cys Gln Phe Leu Tyr Pro Ala Ly - #s Lys# 40- (2) INFORMATION FOR SEQ ID NO: 89:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#89: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Gln Lys Leu Cys Gln Arg Pro Ser Gly Thr Tr - #p Ser Gly Val Cys Gly# 150- Asn Asn Asn Ala Cys Lys Asn Gln Cys Ile Ar - #g Leu Glu Lys Ala Arg# 30- His Gly Ser Cys 35- (2) INFORMATION FOR SEQ ID NO: 90:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#90: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Gln Arg Val Cys Asn Lys Pro Ser Gly Thr Tr - #p Ser Gly Leu Cys Gly# 150- Asn Asn Asn Ala Cys Arg Gln Asn Cys Ile Ly - #s Val Asp Arg Ala Lys# 30- Lys Gly Ser Cys 35- (2) INFORMATION FOR SEQ ID NO: 91:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#91: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Met Leu Glu Glu Leu Phe Glu Glu Met Thr Gl - #u Phe Ile Glu Glu Val# 150- Ile Glu Thr Met 20- (2) INFORMATION FOR SEQ ID NO: 92:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1228 (B) TYPE: NUCLEIC ACID#STRANDED (C) STRANDEDNESS: DOUBLE (D) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE:#DNA AND OTHER NUCLEIC ACIDGENOMIC#92: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:# 50TATCGA TTTAAATTTC ATCGAAGAGA TTAATATCGA# 100ACTTTA AATACATAAC AAATTTTAAA TACATATATC# 150TTTTTT AAAGTCATGA AGTATGTATC AAATACACAT# 200CTATTC ATAATTTAAA AAATAGAAAA GATACATCTA# 250ATGTAT CAAATACATT AGGAAAAGGG CATATATCTT# 300ACGATT TTGATTTATG TATAATTTCC AAATGAAGGT# 350GAAATA ACAATATACT TTTATCAGAA CATTCAACAA# 400AGAGTG AAAAATACAC ATTGTTCTCT AGACATACAA# 450TCTCAA AATTTAGAGA AACAAATCTG AATTTCTAGA# 500ATGCAC TTTGCTATTG CTCGAAAAAT AAATGAAAGA# 550AAAAGA TGTTAGACTA GATATACTCA AAAGCTATTA# 600TTCTTA CATTAAGTAT TTTAGTTACA GTCCTGTAAT# 650AGATTG TATCTAAACT TAAATGTATC TAGAATACAT# 700CATATA CATGTATCCG ACACACCAAT TCTCATAAAA# 750AACTAA TTTATCCTTC AAGTCAACTT AAGCCCAATA# 800TAAAGG CCCAAGTGGC ACAAAATGTC AGGCCCAATT# 850TTGTAA AACCCTAATA AAGTGGCACT GGCAGAGCTT# 900TCAACA AAGAAACCCT AAAAGCCGCA GCGCCACTGA- TTTCTCTCCT CCAGGCGAAG ATG CAG ATC TTC GTG AAG AC - #C TTA#944# Met Gln Ile Phe Val Lys Thr Leu# 5 1- ACG GGG AAG ACG ATC ACC CTA GAG GTT GAG TC - #T TCC GAC ACC# 986Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Se - #r Ser Asp Thr# 20- ATC GAC AAT GTC AAA GCC AAG ATC CAG GAC AA - #G GAA GGG ATT#1028Ile Asp Asn Val Lys Ala Lys Ile Gln Asp Ly - #s Glu Gly Ile# 35- CCC CCA GAC CAG CAG CGT TTG ATT TTC GCC GG - #A AAG CAG CTT#1070Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gl - #y Lys Gln Leu# 50- GAG GAT GGT CGT ACT CTT GCC GAC TAC AAC AT - #C CAG AAG GAG#1112Glu Asp Gly Arg Thr Leu Ala Asp Tyr Asn Il - #e Gln Lys Glu# 60# 1148CTC CAT CTC GTG CTC CGT CTC CGT GG - #T GGTSer Thr Leu His Leu Val Leu Arg Leu Arg Gl - #y Gly#75- GGA TCC GCT GTT AAA AGA GTG GGT CGT AGG TT - #G AAA AAG TTG#1190Gly Ser Ala Val Lys Arg Val Gly Arg Arg Le - #u Lys Lys Leu# 90# 1228T AAG ATT GAT AGG TTA GGA GTT GAT TT - #T TGATCAsp Arg Lys Ile Asp Arg Leu Gly Val Asp Ph - #e# 100- (2) INFORMATION FOR SEQ ID NO: 93:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1154 (B) TYPE: NUCLEIC ACID#STRANDED (C) STRANDEDNESS: DOUBLE (D) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE:#DNA (A) DESCRIPTION: GENOMIC#93: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:# 50TATCGA TTTAAATTTC ATCGAAGAGA TTAATATCGA# 100ACTTTA AATACATAAC AAATTTTAAA TACATATATC# 150TTTTTT AAAGTCATGA AGTATGTATC AAATACACAT# 200CTATTC ATAATTTAAA AAATAGAAAA GATACATCTA# 250ATGTAT CAAATACATT AGGAAAAGGG CATATATCTT# 300ACGATT TTGATTTATG TATAATTTCC AAATGAAGGT# 350GAAATA ACAATATACT TTTATCAGAA CATTCAACAA# 400AGAGTG AAAAATACAC ATTGTTCTCT AGACATACAA# 450TCTCAA AATTTAGAGA AACAAATCTG AATTTCTAGA# 500ATGCAC TTTGCTATTG CTCGAAAAAT AAATGAAAGA# 550AAAAGA TGTTAGACTA GATATACTCA AAAGCTATTA# 600TTCTTA CATTAAGTAT TTTAGTTACA GTCCTGTAAT# 650AGATTG TATCTAAACT TAAATGTATC TAGAATACAT# 700CATATA CATGTATCCG ACACACCAAT TCTCATAAAA# 750AACTAA TTTATCCTTC AAGTCAACTT AAGCCCAATA# 800TAAAGG CCCAAGTGGC ACAAAATGTC AGGCCCAATT# 850TTGTAA AACCCTAATA AAGTGGCACT GGCAGAGCTT# 900TCAACA AAGAAACCCT AAAAGCCGCA GCGCCACTGA- TTTCTCTCCT CCAGGCGAAG ATG CAG ATC TTC GTG AAG AC - #C TTA#944# Met Gln Ile Phe Val Lys Thr Leu# 5 1- ACG GGG AAG ACG ATC ACC CTA GAG GTT GAG TC - #T TCC GAC ACC# 986Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Se - #r Ser Asp Thr# 20- ATC GAC AAT GTC AAA GCC AAG ATC CAG GAC AA - #G GAA GGG ATT#1028Ile Asp Asn Val Lys Ala Lys Ile Gln Asp Ly - #s Glu Gly Ile# 35- CCC CCA GAC CAG CAG CGT TTG ATT TTC GCC GG - #A AAG CAG CTT#1070Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gl - #y Lys Gln Leu# 50- GAG GAT GGT CGT ACT CTT GCC GAC TAC AAC AT - #C CAG AAG GAG#1112Glu Asp Gly Arg Thr Leu Ala Asp Tyr Asn Il - #e Gln Lys Glu# 60- TCA ACT CTC CAT CTC GTG CTC CGT CTC CGT GG - #T GGT GGA TCC#1154Ser Thr Leu His Leu Val Leu Arg Leu Arg Gl - #y Gly Gly Ser#75- (2) INFORMATION FOR SEQ ID NO: 94:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 78 (B) TYPE: AMINO ACID (D) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE#94: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Met Gln Ile Phe Val Lys Thr Leu 1 5- Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Se - #r Ser Asp Thr# 20- Ile Asp Asn Val Lys Ala Lys Ile Gln Asp Ly - #s Glu Gly Ile# 35- Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gl - #y Lys Gln Leu# 50- Glu Asp Gly Arg Thr Leu Ala Asp Tyr Asn Il - #e Gln Lys Glu# 60- Ser Thr Leu His Leu Val Leu Arg Leu Arg Gl - #y Gly Gly Ser#75- (2) INFORMATION FOR SEQ ID NO: 95:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2127 (B) TYPE: NUCLEIC ACID#STRANDED (C) STRANDEDNESS: DOUBLE (D) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE:#DNA AND OTHER DNARIPTION: GENOMIC#95: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:# 50TTGAAC ATATAAATAA ATATAAATTG TCTCAATAAT# 100ATATTT GAAATCTCAA TTTTATGATT TTTTAAATTC# 150ACAATT TNCANCTTCA AAAAGTTTTA TTAAANATTT# 200GATGAG GATGACAAGA TNTTGGTCAT CAATTACATA# 250AGTAAG CAACTTCAAT GTTTTTCATA ATGATAATGA# 300ACCCAT TTATTATTCA CATTGATTGA GTTTTATATG# 350TAATAA TATTTCTTAT AAAGCAAGAG GTCAATTTTT# 400CGTCAC TAAATTATAT TTGATAATGT AAAACAATTC# 450TATCAT GAAATAAACT ATTTTTATAA CCAAATTACT# 500AAAAAA AGTCATTAAG AAGACATAAA ATAAATTTGA# 550GTCGAC TGACTTTTTT TTTTTTTATC ATAAGAAAAT# 600AACCTA ATAAAACACT AATATAATTT CATGGAATCT# 650AGAAAT AAGAAAAAGT GTTTCTAATA GACCCTCAAT# 700TTCAAT CAAATTTAAA TAACAAATAT CAATATGAGG# 750AAAATA ATATGAAAAA AGAGCAATAC ATAATATAAG# 800CGATTA TCAAGGTAGT ATTATATCCT AATTTGCTAA# 850TATTTA AGGTCATGTT CATGATAAAC TTGAAATGCG# 900ATATTA AAATAAAAAA ATACCTAAAA TAAAATTAAG# 950TATTTT TTTACATGAC CTACATTTTT CTGGGTTTTT# 1000AAGTGT CGACCTCATT CTCCTAATTT TCCCCACCAC# 1050GGAAAG GTAGCTTTTG CGTGTTGTTT TGGTACACTA# 1100ACGTGT CCTCATATAA TTGGTTAACC CTATGAGGCG# 1150CGGCCA TGCCATCTAT AAAATGAAGC TTTCTGCACC# 1200TTCTAT CTGATTTCTA TTATAATTTC TCTCAATTGC# 1240 AAGG TTAGAATCTT CTCTATTTTT# 1290TAGATT CTCGAATTAG CTAATCAGGC GCTGTTATAG# 1340TCTCTC CTCGGTTGTC TTGATGGAAA AGGCCTAACA# 1390CGTCTG GTTTGATGGA AAAGGCCTAC AATTGGCCGT# 1440TTGATG AAAAAGCCCC TAGTTTGAGA TTTTTTTTCT# 1490AGGTTT AAAATTAGAG TTTTTACATT TGTTTGATGA# 1540TTGAGT TTTTCCGGTT GATTTGATGA AAAAGCCCTA# 1590CCGTCG GTTTGATTCT GAAGGCCTAA AATTTGAGTT# 1640GATGAA AAAGCCCTAA ATTTGAGTTT CTCCGGCTGT# 1690CCTAAA TTTGAAGTTT TTTCCCCGTG TTTTAGATTG# 1740CTCGAA TCAGCTAATC AGGGAGTGTG AAAGCCCTAA# 1788TTGT TCTGATTGTT GTTTTTATGA ATTTGCAG- ATG CAG ATC TTT GTG AAA ACT CTC ACC GGA AA - #G ACT ATC ACC#1830Met Gln Ile Phe Val Lys Thr Leu Thr Gly Ly - #s Thr Ile Thr# 10- CTA GAG GTG GAA AGT TCT GAT ACA ATC GAC AA - #C GTT AAG GCT#1872Leu Glu Val Glu Ser Ser Asp Thr Ile Asp As - #n Val Lys Ala#25- AAG ATC CAG GAT AAG GAA GGA ATT CCC CCG GA - #T CAG CAA AGG#1914Lys Ile Glu Asp Lys Glu Gly Ile Pro Pro As - #p Gln Gln Arg# 40- CTT ATC TTC GCC GGA AAG CAG TTG GAG GAC GG - #A CGT ACT CTA#1956Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gl - #y Arg Thr Leu# 55- GCT GAT TAC AAC ATC CAG AAG GAG TCT ACC CT - #C CAT TTG GTG#1998Ala Asp Tyr Asn Ile Gln Lys Glu Ser Thr Le - #u His Leu Val# 70- CTC CGT CTA CGT GGA GGT GGA TCC GCT GTT AA - #A AGA GTG GGT#2040Leu Arg Leu Arg Gly Gly Gly Ser Ala Val Ly - #s Arg Val Gly# 80- CGT AGG TTG AAA AAG TTG GAC CGT AAG ATT GA - #T AGG TTA GGA#2082Arg Arg Leu Lys Lys Leu Asp Arg Lys Ile As - #p Arg Leu Gly#95# 2127GAG TCGACCGATC CCCCGAATTT CCCCGAVal Asp Phe 100- (2) INFORMATION FOR SEQ ID NO: 96:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2022 (B) TYPE: NUCLEIC ACID#STRANDED (C) STRANDEDNESS: DOUBLE (D) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE:#DNA (A) DESCRIPTION: GENOMIC#96: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:# 50TTGAAC ATATAAATAA ATATAAATTG TCTCAATAAT# 100ATATTT GAAATCTCAA TTTTATGATT TTTTAAATTC# 150ACAATT TNCANCTTCA AAAAGTTTTA TTAAANATTT# 200GATGAG GATGACAAGA TNTTGGTCAT CAATTACATA# 250AGTAAG CAACTTCAAT GTTTTTCATA ATGATAATGA# 300ACCCAT TTATTATTCA CATTGATTGA GTTTTATATG# 350TAATAA TATTTCTTAT AAAGCAAGAG GTCAATTTTT# 400CGTCAC TAAATTATAT TTGATAATGT AAAACAATTC# 450TATCAT GAAATAAACT ATTTTTATAA CCAAATTACT# 500AAAAAA AGTCATTAAG AAGACATAAA ATAAATTTGA# 550GTCGAC TGACTTTTTT TTTTTTTATC ATAAGAAAAT# 600AACCTA ATAAAACACT AATATAATTT CATGGAATCT# 650AGAAAT AAGAAAAAGT GTTTCTAATA GACCCTCAAT# 700TTCAAT CAAATTTAAA TAACAAATAT CAATATGAGG# 750AAAATA ATATGAAAAA AGAGCAATAC ATAATATAAG# 800CGATTA TCAAGGTAGT ATTATATCCT AATTTGCTAA# 850TATTTA AGGTCATGTT CATGATAAAC TTGAAATGCG# 900ATATTA AAATAAAAAA ATACCTAAAA TAAAATTAAG# 950TATTTT TTTACATGAC CTACATTTTT CTGGGTTTTT# 1000AAGTGT CGACCTCATT CTCCTAATTT TCCCCACCAC# 1050GGAAAG GTAGCTTTTG CGTGTTGTTT TGGTACACTA# 1100ACGTGT CCTCATATAA TTGGTTAACC CTATGAGGCG# 1150CGGCCA TGCCATCTAT AAAATGAAGC TTTCTGCACC# 1200TTCTAT CTGATTTCTA TTATAATTTC TCTCAATTGC# 1240 AAGG TTAGAATCTT CTCTATTTTT# 1290TAGATT CTCGAATTAG CTAATCAGGC GCTGTTATAG# 1340TCTCTC CTCGGTTGTC TTGATGGAAA AGGCCTAACA# 1390CGTCTG GTTTGATGGA AAAGGCCTAC AATTGGCCGT# 1440TTGATG AAAAAGCCCC TAGTTTGAGA TTTTTTTTCT# 1490AGGTTT AAAATTAGAG TTTTTACATT TGTTTGATGA# 1540TTGAGT TTTTCCGGTT GATTTGATGA AAAAGCCCTA# 1590CCGTCG GTTTGATTCT GAAGGCCTAA AATTTGAGTT# 1640GATGAA AAAGCCCTAA ATTTGAGTTT CTCCGGCTGT# 1690CCTAAA TTTGAAGTTT TTTCCCCGTG TTTTAGATTG# 1740CTCGAA TCAGCTAATC AGGGAGTGTG AAAGCCCTAA# 1788TTGT TCTGATTGTT GTTTTTATGA ATTTGCAG- ATG CAG ATC TTT GTG AAA ACT CTC ACC GGA AA - #G ACT ATC ACC#1830Met Gln Ile Phe Val Lys Thr Leu Thr Gly Ly - #s Thr Ile Thr# 10- CTA GAG GTG GAA AGT TCT GAT ACA ATC GAC AA - #C GTT AAG GCT#1872Leu Glu Val Glu Ser Ser Asp Thr Ile Asp As - #n Val Lys Ala#25- AAG ATC CAG GAT AAG GAA GGA ATT CCC CCG GA - #T CAG CAA AGG#1914Lys Ile Glu Asp Lys Glu Gly Ile Pro Pro As - #p Gln Gln Arg# 40- CTT ATC TTC GCC GGA AAG CAG TTG GAG GAC GG - #A CGT ACT CTA#1956Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gl - #y Arg Thr Leu# 55- GCT GAT TAC AAC ATC CAG AAG GAG TCT ACC CT - #C CAT TTG GTG#1998Ala Asp Tyr Asn Ile Gln Lys Glu Ser Thr Le - #u His Leu Val# 70# 2022GA GGT GGA TCCLeu Arg Leu Arg Gly Gly Gly Ser 75- (2) INFORMATION FOR SEQ ID NO: 97:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#97: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Lys Arg Lys Arg Ala Val Lys Arg Val Gly Ar - #g Arg Leu Lys Lys Leu# 15- Ala Arg Lys Ile Ala Arg Leu Gly Val Ala Ly - #s Leu Ala Gly Leu Arg# 305- Ala Val Leu Lys Phe 35- (2) INFORMATION FOR SEQ ID NO: 98:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 (B) TYPE: AMINO ACID (C) TOPOLOGY: LINEAR- (ii) MOLECULE TYPE: (A) DESCRIPTION: PEPTIDE- (iii) HYPOTHETICAL: NO- (v) FRAGMENT TYPE: COMPLETE PEPTIDE- (vi) ORIGINAL SOURCE: SYNTHETIC- (vii) IMMEDIATE SOURCE: SYNTHETIC- (x) PUBLICATION INFORMATION: NOT PREVIOU - #SLY PUBLISHED#98: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:- Ala Val Lys Arg Val Gly Arg Arg Leu Lys Ly - #s Leu Asp Arg Lys Ile# 15- Asp Arg Leu Gly Val Asp Phe 20__________________________________________________________________________

Claims

1. A lytic peptide comprising the amino acid sequence of SEQ ID NO. 97 .

2. A lytic peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS. 48, 55-65.

3. A lytic peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS. 66-80.

4. A lytic peptide of claim 2 wherein the peptide has the amino acid sequence of SEQ ID NO. 57.

5. A lytic peptide of claim 3 wherein the peptide has the amino acid sequence of SEQ ID NO. 66.

6. A lytic peptide of claim 2 wherein the peptide has the amino acid sequence of SEQ ID NO. 48.